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ABSTRACT 
Decidual stromal cells (DSCs) play a pivotal role in feto-maternal tolerance to prevent 
rejection of the fetus during pregnancy. This provides a rationale for immunomodulatory 
stromal cells from the placenta being isolated and used as cellular therapy for inflammatory 
conditions following hematopoietic stem cell transplantation (HSCT). The term placenta 
provides a ready source of cells, since this tissue is normally discarded after delivery.  
Stromal cells were isolated from different parts of the term placenta, specifically chorionic 
villi, umbilical cord, and the fetal membranes. DSCs isolated from the fetal membranes had a 
consistent immunosuppressive capacity in vitro comparable to that of bone marrow-derived 
mesenchymal stromal cells (MSCs). This immune suppression was partly contact-dependent. 
Factors of importance in this process were found to include interferon-γ (IFN-γ), 
prostaglandin E2, indoleamine-2,3-dioxygenase (IDO), and programmed death ligand 1 
(PD-L1). In addition, IDO was found to play a role in the DSC-mediated induction of 
regulatory T cells (Tregs) in vitro. The addition of DSCs to the allogeneic setting in vitro also 
resulted in a reduction in the concentration of cytokines IFN-γ and interleukin (IL)-17, while 
the concentrations of IL-10 and IL-2 were elevated. There was also a correlation between 
increased IL-2 levels and reduced expression of the high-affinity IL-2 receptor on 
alloantigen-activated T cells. This was consistent with a reduced phosphorylation of STAT5 
and reduced uptake of IL-2 in the cultures. The reduced sensitivity to IL-2 was not found to 
be correlated to an increased exhaustion state, based on expression of programmed death 1 
(PD-1) and CD95.  
Further characterization of DSCs showed that they have limited differentiation capacity, that 
they are of maternal origin, and that they have high expression of co-inhibitory markers and 
integrins that are of importance for migration to inflamed tissue. The expression of these 
markers was elevated in the presence of external IFN-γ. In contrast, addition of IFN-γ did not 
increase the antiproliferative effect of DSCs in vitro.   
DSCs were expanded to high cell numbers at low passage number. These DSCs were then 
introduced as a treatment for severe graft-versus-host disease (GVHD), a common 
complication after HSCT with high mortality rates. In an initial pilot study, nine patients were 
treated with DSCs. In eight patients who could be evaluated, the overall response rate was 
75% and three patients were alive six months after transplant. In a larger patient cohort, 
immune parameters were monitored up to four weeks after DSC intervention. The patients 
were divided into two groups, responders and non-responders, depending on GVHD status 
after DSC treatment. Increased plasma concentrations of IL-6, IL-8, and IP-10 distinctly 
differentiated the non-responders from the responders before DSC intervention. Although the 
expression of HLA-DR decreased over time in the CD4+ compartment of the responders, the 
same group had increasing expression of CCR9 in several cell subsets, including CD4+ T 
cells, B cells, and monocytes. The responders also had less naïve CD4+ T cells one week 
after DSC intervention.  
Thus, DSCs can be isolated from term placentas and can be expanded to high cell numbers at 
low passage number. The DSCs have immunomodulatory functions, mediated by several 
factors. DSCs may be used as a treatment for GVHD, and improvement in GVHD may be 
distinguished by a specific immune profile.   
  
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Immunsystemet spelar en avgörande roll i människans skydd mot infektioner och cancer. 
Störningar i immunsystemets funktion kan bland annat resultera i autoimmuna sjukdomar och 
infektionskänslighet. Om en patient har ett dysfunktionellt immunsystem, eller drabbas av 
leukemi, kan hen behöva en allogen (inte genetiskt identisk) stamcellstransplantation, tidigare 
kallat benmärgstransplantation. En sådan innebär att de blodbildande stamcellerna byts ut 
mot nya celler från en frisk donator.  
Ett transplanterat organ, exempelvis en njure eller en lever, kan stötas bort av patientens 
immunsystem då transplantatet känns igen som icke kroppseget, allogent. Det kan även 
inträffa vid en stamcellstransplantation, men då kommer istället det nytransplanterade 
immunsystemet attackera patientens vävnader. Detta kallas för transplantat-kontra-värd 
sjukdom (eng. graft-versus-host disease, GVHD) och är en inflammatorisk komplikation efter 
transplantation som drivs av immunceller, främst T celler, från transplantatet. Akut GVHD 
drabbar främst organ såsom hud, tarm och lever. Vid svår GVHD är behandlingsalternativen 
få och dödligheten hög. 
Under graviditeten har moderkakan flera uppgifter, inklusive att ge näring och syre, samt 
hindra moderns immunförsvar från att attackera det allogena fostret. Idén som ligger till 
grund för denna avhandling är att celler från moderkakan med påverkan på immunsystemet 
skulle kunna användas som behandling och minska inflammationen vid GVHD. Moderkakan 
slängs vanligtvis efter förlossningen, varför det är lätt att etiskt försvara användandet av 
vävnaden för forskning och behandling.  
I en första studie isolerades stromaceller (bindvävsceller) från olika delar av moderkakan och 
cellernas påverkan på immunsystemet jämfördes i laboratoriemiljö (in vitro). I analysen 
inkluderades även stromaceller från benmärg (MSCs) som tidigare använts som cellterapi för 
GVHD. Studien visade att deciduala stromaceller (DSCs) isolerade från fosterhinnorna 
konsekvent kunde minska allogent framkallad tillväxt av immunceller i odlingskulturer in 
vitro. DSCs inducerade även förekomst av lösliga faktorer med en anti-inflammatorisk profil. 
På cellytan av DSCs kunde vi identifiera ett uttryck av flera molekyler som är viktiga vid 
migration till inflammerad vävnad. Detta uttryck var högre om cellerna förbehandlades med 
signalmolekylen IFN-γ. Vidare kunde vi visa att DSCs hade begränsade stamcellsegenskaper. 
DSCs hade samma DNA som moderkaksdonatorn vilket bekräftade att de kom från deciduan, 
alltså den förändrade livmoderslemhinnan som utvecklas under graviditeten. Det var också 
lätt att snabbt odla upp stora mängder celler, vilket är en stor fördel om de ska användas vid 
behandling. 
Ytterligare studier in vitro visade att DSCs delvis kräver direkt cellkontakt med immunceller 
för att verka. Vi identifierade ett flertal faktorer (IDO, IFN-γ, PGE2, PD-L1) som var viktiga 
för denna immunologiska påverkan. Därtill fann vi att immunhämmande regulatoriska T 
celler ökar i proportion till övriga immunceller. Dessa fynd är i linje med andra studier som 
undersöker dessa fenomen i en liknande kontext. 
En löslig faktor som leder till tillväxt av immunceller, specifikt T-celler, är cytokinen IL-2. 
En av våra fördjupade studier visade att om DSCs tillsattes i allogena cellkulturer så 
minskades uttrycket av receptorn för IL-2 på aktiverade T-celler. Vi tolkade denna 
observation som att DSCs först stimulerar till en hög produktion av IL-2 i immunceller. Den 
höga koncentrationen av IL-2 leder sedan till att dess receptor på cellytan minskar i uttryck. 
Cellerna får som en konsekvens en minskad förmåga att svara på stimuli från IL-2. Detta 
kunde bekräftas i experiment där den intracellulära signaleringen av IL-2 hämmades. Härmed 
identifierades ytterligare en möjlig immunologisk effekt som skulle kunna förklara varför 
DSCs minskar celltillväxt av immunceller in vitro.  
Baserat på de studier där DSCs påverkan på immunsystemet undersökts in vitro användes 
dessa celler som behandling för allvarlig GVHD. I en första pilotstudie behandlades nio 
patienter. Av de åtta patienterna som kunde utvärderas hade sex stycken en initial förbättring 
av sina GVHD-symptom. Tre patienter levde vid halvårsuppföljningen. Dessa resultat är 
jämförbara med andra experimentella terapier för GVHD.  
Slutligen gjordes en omfattande studie ex vivo där immunparametrar (lösliga faktorer och 
immuncellstyper) undersöktes i blodprover som tagits från 22 patienter som behandlats med 
DSCs för allvarlig GVHD. Målet var att undersöka hur immunsystemet påverkas av 
cellterapin, samt om det fanns faktorer som kunde förutsäga hur patienten skulle svara på 
behandlingen. Vi identifierade höga koncentrationer av tre lösliga faktorer, IL-6, IL-8 och IP-
10, i blodet hos patienter som inte svarade på behandlingen. Patienter som svarade på 
behandlingen med DSCs hade ett minskat uttryck av aktiveringsmarkören HLA-DR på T 
celler. Samma patientgrupp hade även en minskad andel T celler med en naiv fenotyp jämfört 
med gruppen av patienter som inte förbättrade sin GVHD. Patienter som blev bättre efter 
behandling hade också en immunprofil som indikerade att immuncellerna i blodet hade en 
ökad förmåga att migrera till tarmen. Förändringar i immuncellers fenotyp på grund av 
tillsatta DSCs som kunde observeras in vitro kunde dock inte observeras ex vivo. 
Sammanfattningsvis har vi i fem studier isolerat och expanderat deciduala stromaceller från 
moderkakan. Vi har bidragit till att kartlägga dessa cellers påverkan på immuncellers 
egenskaper in vitro. Vi använde cellerna som behandling för GVHD och undersökte 
immunologiska parametrar som visat sig vara viktiga i samband med GVHD. Ett flertal 
faktorer identifierades som kan vara vägledande för att prognosticera utfallet efter 
behandling. Randomiserade kliniska fas I/II studier, optimering av pre-kliniska och kliniska 
protokoll, och vidare studier där bindvävscellers immunreglerande egenskaper undersöks i 
detalj är centralt vid fortsatt forskning. Detta för att ge ytterligare insikt om hur cellterapi kan 
användas effektivt för att behandla svåra inflammatoriska tillstånd.  
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1 INTRODUCTION 
The immune system is one of the most complicated and fascinating parts of human 
physiology. The immune system has evolved in a way that lets it defend the host in a safe and 
efficient manner. However, the immune system also has some important limitations. Disease 
development originates from a failure of the immune system to successfully complete a 
number of checkpoints. Firstly, immune cells will detect the presence of unknown antigens 
(e.g. from pathogens such as bacteria and viruses). Secondly, the immune recognition will 
lead to an immune effector function with the purpose of eradicating the unknown pathogen. 
This effector function must be regulated in order to prevent an overreaction, and also to 
promote a return to homeostasis after the infection has been cleared. Immune regulation is 
therefore vital in balancing the immune response. Lastly, the adaptive immune system will 
develop memory for any particular pathogen that is encountered, and mobilize a quick 
immune response following further encounter with the pathogen.  
Just as the immune system must recognize a pathogen, mount an effector response, regulate 
it, and develop memory to prevent recurrent infectious disease, the same system is used by 
the immune system to eradicate cancer cells. In this respect, immune regulation plays a 
crucial role. The immune system must be able to detect and eradicate autologous cancer cells, 
but it cannot be too sensitive and activate a response to small natural variations―and induce 
autoimmunity. The immune system therefore has a key role in a wide range of diseases, 
including infections, cancer, and autoimmunity. 
This thesis will focus on immune regulation following allogeneic hematopoietic stem cell 
transplantation (HSCT). HSCT is a potentially curative treatment for hematological 
malignancies, aplastic anemia and inborn errors of metabolism. However, the introduction of 
an allogeneic immune system in a patient fundamentally changes the concept of immune 
regulation. The transplanted immune system must initiate a response to microorganisms and 
residual cancer cells while minimizing any damage to healthy allogeneic tissue. Furthermore, 
the heavy conditioning regimen used before the transplant introduces abnormalities in several 
layers of immune homeostasis, which may trigger an allogeneic response. 
Immunosuppressive drugs are used to balance the allogeneic response in order to maintain an 
immune response against remaining cancer cells, while preventing the immune cells from 
attacking healthy tissue. This thesis will concentrate on immune regulation where there is a 
strong allogeneic reaction and I will present some circumstances in which stromal cells 
isolated from the placenta may influence alloreactive immune cells. The emphasis will be on 
T cells, which are key mediators of the alloreaction by the newly transplanted immune 
system. Clinically, this manifests as graft-versus-host disease (GVHD).  
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1.1 TRANSPLANTATION IMMUNOLOGY 
1.1.1 Immunobiology 
1.1.1.1 A very brief introduction to the immune system 
The work performed for this thesis mostly involved studies of adaptive immunity, and 
specifically T cells. The introduction to the immune system in this thesis will therefore 
mainly cover important background information that is of relevance for discussion of the 
results presented in studies I‒V. There are, however, excellent reviews in the literature that 
provide a thorough introduction to the immune system1,2.  
The immune system is not only composed of the immune cells that originate from the bone 
marrow. The first lines of defense against external pathogens are physical barriers such as 
skin and mucosa. Antimicrobial peptides, pH-variations, and commensal microbiota can 
further improve the effectiveness of physical barriers. The complement system is composed 
of a number of molecules that circulate in blood. It is an important part of the defense against 
infection and augments the functions of innate and adaptive immunity.  
Hematopoietic stem cells (HSCs) mainly develop in the bone marrow. As the name suggests, 
HSCT is the procedure whereby the patient’s HSCs are removed and replaced with HSCs 
from a donor. The new HSCs will proliferate and differentiate into cells that populate the 
blood, bone marrow, lymphatic organs, and other tissues. The hematopoiesis, with all the cell 
types that originate from HSCs, is illustrated in Figure 1.    
Differentiation from HSCs can be seen as two specific lineages, the myeloid lineage and the 
lymphoid lineage. Functionally, the immune cells originating from the hematopoiesis can be 
involved in innate immunity or in adaptive immunity. The innate arm of the immune system 
includes the phagocyting neutrophils and macrophages (derived from monocytes), as well as 
eosinophils, basophils, mast cells and natural killer (NK) cells. Physical barriers and 
complement are also regarded as a part of the innate immune system. The adaptive immune 
system includes T cells and B cells. Dendritic cells are often referred to as being a bridge 
between innate immunity and adaptive immunity, as they use the products from the innate 
immune system to activate the adaptive immune system.  
The innate immune system mounts a response to a pathogen more rapidly than the adaptive 
immune system. The cells in the innate immune system have the ability to respond to 
genetically conserved structures on pathogens (e.g. bacterial/viral DNA/RNA, 
lipopolysaccharides (LPS), and immune complexes (ICs)). A broad range of microbes 
express these conserved structures, which enables the innate immune system to quickly 
respond to most pathogens. The innate immune system is, however, restricted to responding 
to certain evolutionary conserved stimuli only, and it may need help from the adaptive 
immune system to eradicate pathogens.  
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Figure 1. Simplified scheme showing the hematopoiesis.  
Monocytes and macrophages are part of the innate immune system. The main task of 
macrophages is to phagocytose pathogens and debris such as dead cells during and after an 
immune response. Monocytes and macrophages also have the function of acting as antigen-
presenting cells (APCs). This means that they are efficient in presenting peptides (foreign or 
self) to the adaptive immune system, thus working as a bridge between the innate immune 
system and the adaptive immune system. The subset of cells that specializes in antigen 
presentation is the dendritic cells3. Macrophages will be covered in more detail later.  
The adaptive immune system is distinctly different from the innate immune system. The time 
taken for the adaptive immune system to deal with a pathogen is longer than the time taken 
by the innate arm of the immune system. However, the cell-mediated adaptive immune 
response is specific and very potent. As the name suggests, the adaptive immune system has 
the ability to recognize most structures, even though they have never been encountered 
before. Structures that are able to induce an immunological response are called antigens. The 
development of B and T cells includes a random recombination of their B and T cell 
receptors, making each B and T cell clone unique in its ability to recognize one specific 
antigen4,5. The entire T and B cell repertoire can therefore recognize a very diverse set of 
antigens. Antigens are mainly presented to T cells and to B cells in secondary lymphoid 
organs6. B cells can detect antigens in their native form, whereas the antigens have to be 
presented on major histocompatibility complexes (MHCs, in humans referred to as human 
leukocyte antigens, HLA) for T cells7,8. There are two main types of MHC, namely MHC 
class I and MHC class II. MHC class I is present on all nucleated cells in the body whereas 
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MHC class II is more restricted to certain types of cells in the immune system. For instance, 
MHC class II is constitutively expressed on dendritic cells, monocytes, and macrophages. 
MHC class II may also be expressed on B cells. Other non-immune cells such as epithelial 
cells or stromal cells may express MHC class II. If a certain T or B cell clone recognizes a 
specific antigen, the cell(s) will become activated, proliferate, and exert its/their effector 
function. After the pathogen has been cleared, most of the effector cells will go into 
apoptosis. Some cells will remain as memory cells. The next time the same antigen is 
encountered, these memory cells can become quickly activated and respond to the pathogen. 
This is acquired immunity.  
 
1.1.1.2 T cell development  
As briefly touched upon earlier, T cells must be tightly regulated in order to recognize foreign 
pathogens or detect malignant cells while not reacting to healthy tissue. The entire maturation 
process of the T cell during which these properties are acquired takes place in the thymus. 
Immature T cells, or thymocytes, are produced in the bone marrow and subsequently migrate 
to the thymus. When the thymocytes arrive in the thymus, they do not express the 
characteristic surface proteins that are used to identify mature T cells: cluster of 
differentiation (CD)3, the T cell receptor (TCR), CD4, or CD8. Since thymocytes do not 
express either CD4 nor CD8, they are referred to as double-negative thymocytes. After 
maturation, the thymocytes will comprise three functionally different types of immune cells: 
conventional αβT cells, γδT cells, and invariant NKT cells. The latter two types will not be 
described further since they are beyond the scope of this thesis. The maturation of a 
functional T cell from a thymocyte can be divided into seven distinct checkpoints. The first 
four developmental stages of double-negative thymocytes are designated DN1‒DN4, and 
each stage can be identified by the variance in expression of CD44 and CD259. The following 
two stages are when the thymocytes have a double-positive expression of CD4 and CD8. The 
last stage is the negative selection.  
Cells in the DN1 stage express CD44. This expression is reduced during DN3, and 
thymocytes in DN4 do not express CD44. In DN2, the thymocytes start to express CD25. 
This expression is then lost during DN4. DN1 thymocytes also express c-kit10, which is 
gradually lost during the later stages. Notch signaling is important during the entire selection 
process11-13. The diversity of the T cell repertoire arises from rearrangement of the TCR gene, 
which yields T cells with unique TCRs. Rearrangement of the TCRβ-chain occurs in DN2‒3. 
If the rearrangement is successful, further rearrangement of the β-chain is inhibited and the 
chain is paired with CD3 and a surrogate α-chain. This pre-TCR complex is able to initiate 
ligand-independent signaling, leading to proliferation and expression of both CD4 and CD814. 
Following expansion, the thymocyte starts rearrangement of the α-chain. If the TCR is then 
able to recognize an MHC complex with a self-peptide, the thymocyte successfully 
undergoes positive selection and will not face the same apoptotic fate as those thymocytes 
that fail to recognize the self-MHC:self-peptide complex15,16. The thymocytes now stop 
expressing both CD4 and CD8. Depending on the stimuli, the cells commit to either CD4 or 
CD817-21. CD4 and CD8 will be associated with recognition of a specific type of MHC 
molecule. CD4-expressing cells will have a TCR that recognizes MHC class II, while CD8 
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cells will recognize MHC class I.  In the negative selection, the thymocyte is again exposed 
to self-MHC:self-peptide. If the thymocyte becomes activated by the self-MHC:self-peptide, 
the thymocyte will fail negative selection and undergo apoptosis22-24. The negative selection 
prevents autologous reactivity to healthy tissue. The thymocytes that pass negative selection 
will move on and leave the thymus as naïve T cells.  
 
1.1.1.3 T cell activation and differentiation  
The primary sites in vivo where T cell activation occurs are the secondary lymphoid organs 
(e.g. the lymph nodes, spleen, Peyer’s patches, tonsils, and adenoids), which are distributed 
over the entire body. There, peptides collected from the surrounding tissues will be 
presented to the T cells by APCs. Both APCs that have migrated from the tissues and APCs 
resident in lymph nodes are important in the priming of T cells25. Guided by stochastic 
forces and by chemokines, the T cell will scout the surrounding APCs for MHC ligands 
with peptides to which the T cell is destined to respond since its priming in the thymus. The 
interface between the T cell and the APC where the signaling occurs is referred to as the 
immunological synapse26,27. When the T cell encounters an activated APC that displays 
MHC-peptide complexes with high affinity for its TCR, the T cell can become activated, 
but it also requires other signals from the APC. First, there must be an interaction between 
the TCR (CD4/CD8) and the MHC molecule with peptide. The binding between the T cell 
and the APC is enhanced by integrins and their respective ligands. Examples of integrin-
ligand interactions in the immunological synapse are LFA-1 and CD2 on T cells, and 
intracellular adhesion molecule (ICAM)-1 and CD48/CD59 on APCs. T cells are very 
sensitive to activation. As little as 100 specific MHC-peptide complexes or less on the APC 
is enough to activate the T cell28,29. There have also been reports showing that T cells can 
respond to as little as one single MHC class II peptide30. CD4 or CD8 is important to 
achieve this low degree of sensitivity31. Additionally, the T cell must receive co-stimulatory 
signals to become activated, proliferate, and survive. The most important co-stimulatory 
molecule on T cells is CD2832,33. CD80 and CD86 are expressed on APCs and binds to 
CD2829. Alteration of this co-stimulation is crucial for the regulation of T cell activation 
and survival. For instance, CD28 signaling is subject to feedback inhibition by reduction of 
CD28 synthesis34. There are also inhibitory molecules on T cells, such as PD-135,36 and 
cytotoxic T-lymphocyte-associated protein (CTLA)-4, that may regulate signaling and T 
cell activation37. Other co-stimulatory molecules present on T cells that may boost 
activation are inducible T cell co-stimulator (ICOS) (a member of the immunoglobulin 
superfamily, just as CD28) and members of the tumor necrosis factor (TNF) superfamily 
(e.g. CD40L and CD2738). Cytokines also play an important role in the activation, 
expansion, and differentiation of T cells. The most well recognized cytokine is interleukin-
2 (IL-2), which is crucial for regulating conventional T cell differentiation and expansion39-
41. IL-2 and the IL-2 receptor (IL-2R) will be covered in more detail later due to their 
specific relevance in Paper IV. 
Once a T cell is activated, it will proliferate and differentiate into effector cells. However, 
there is a difference in activation threshold between helper T cells (from now on referred to 
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as CD4+ T cells) and cytotoxic T cells (from now on referred to as CD8+ T cells). CD8+ T 
cells have a higher threshold for activation than CD4+ T cells. In fact, one role of CD4+ T 
cells is to enhance activation signals in order to activate CD8+ T cells. For instance, 
signaling through CD40/CD40L42 between an APC and a CD4+ T cell may enable priming 
of the CD8+ T cell. The reason for CD8+ T cells being more tightly regulated may be the 
destructive function of effector CD8+ T cells. The signature function of CD8+ T cells is 
their cytotoxic ability. There are two main types of cytotoxicity. The CD8+ T cell can 
release perforin43 and granzymes to initiate apoptosis. This cell can also use the Fas lytic 
pathway to initiate apoptosis44 . The targets of CD8+ T cells are cells that present MHC 
ligand:peptide complexes that binds to the TCR of the CD8. This allows the adaptive 
immune system to fight intracellular pathogens such as viruses and certain intracellular 
bacteria, but CD8+ T cells are also important in tumor surveillance45. NK cells also have 
cytotoxic ability, and complement T cells in the defense against tumors46,47. Although 
cytotoxicity is mostly used by CD8+ T cells and NK cells, CD4+ T cells have also been 
shown to be cytotoxic in some cases48. Antigen-specific cytotoxicity is one of the main 
mechanisms behind graft rejection (in organ transplantation) and GVHD in HSCT. 
 
1.1.1.4 CD4+ T cell subsets 
Different CD4+ T cell subsets were investigated throughout Papers I, III-V. Unlike CD8+T 
cells, which are regarded as one homogenous population in these papers, CD4+ T cells have 
been more rigorously divided into subsets. As the name suggests, the main function of helper 
T cells is to balance the immune response. This can, for example, be to augment CD8+ T cell 
and B cell activation. CD4+ T cells can also induce tolerance, or they can regulate the 
response of other immune cells as well. The main CD4+ subsets investigated in this thesis 
work and the markers that were used to identify them are presented in Figure 2.  
A naïve T cell (TN) that has not yet encountered its antigen roams the circulation and scans 
APCs for an antigen that binds to the TCR49. Since many of the professional APCs reside in 
the secondary lymphoid organs, the T cell must have access. By expressing the chemokine 
receptor CCR7, naïve T cells can enter secondary lymphoid organs50. T cells may also be 
differentiated further from each other based on their expression of CD45 isoforms. Naïve T 
cells express CD45 isoforms with high relative mass, which can be detected with anti-
CD45RA antibodies51. Memory cells will express the CD45 isoform with a lower relative 
molecular mass; this can be detected with anti-CD45RO antibodies. After encountering its 
antigen, the T cell will gain effector function (and be defined as a CD45RA− effector 
memory T cell (TEM)), downregulate CCR7 expression, and increase expression of other 
integrins that are of importance for homing to the site of infection52. However, effector T 
cells defined as CD45RA− central memory T (TCM) cells can express CCR7, which enables a 
quick response to its antigen on a second encounter. These three lineages have the ability to 
proliferate upon activation, and they show plasticity between the three of them. Lastly, a 
fourth subset with low proliferative ability and plasticity―but with high effector 
function―has also been detected53. Studies have shown that reactive T cells that are not naïve 
can indeed also be identified as CD45RA+54. These cells circulate in the periphery and are 
therefore CCR7−. This subset is defined as terminally differentiated T cells (TTD). These are 
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the four stages of T cell maturation and the differentiation pattern of these four lineages is as 
follows: CD45RA+CCR7+ (TN) à CD45RA−CCR7+ (TCM) à CD45RA−CCR7− (TEM)à 
CD45RA+CCR7− (TTD). In this thesis, the maturation pattern presented is implemented on 
both CD8+ and CD4+ T cells.  
CD4+ T cells that are of effector type (CD45RA−) have been divided further based on their 
expression of surface proteins. The two lineages that were first discovered were Th1 and Th2. 
From these two subsets, a theory was developed that the activation of a CD4+ T cell response 
could be classified as a Th1 response or a Th2 response55. A Th1 response is regarded as a 
proinflammatory response, with a high production of interferon-γ (IFN-γ), IL-2, and tumor 
necrosis factor-β (TNF-β). A Th2 response is associated with production of cytokines such as 
IL-4, IL-5, and IL-10. In the last decade, however, additional CD4+ T cell subsets have been 
identified, adding more complexity to the Th1/Th2 model. Apart from Th1 and Th2, the 
subsets investigated in papers III, IV, and V were Th17 and Tregs. Other CD4+ T cell subsets 
that have been identified are for instance T follicular helper cells56 (TFH) and Th957. The most 
characteristic function of TFH cells is their ability to enter B cell follicles and induce antibody 
production. Th9 cells are regarded as proinflammatory. They produce IL-9 and in humans 
they have been shown to be present mostly in the skin.  
Th1 is recognized by secretion of IFN-γ and is associated with inflammation and tissue 
injury. Th1 cells and the cytokines associated with a Th1 response are regarded as being key 
factors in the pathophysiology of GVHD58-60. This is important for activation of macrophages 
and increased protection against intracellular pathogens. The transcription factor that is 
associated with Th1 cells is T-bet61, and IL-12 is important in the induction of Th1 cells62. 
Th1 cells also express the chemokine receptor CXCR363, which was used to identify Th1 
cells in Paper V.  
Th2 cells are induced by IL-464, and one of the master regulators of Th2 cells is the 
transcription factor GATA-365,66. Th2 cells also preferentially express CCR463. The function 
of Th2 is to strengthen the body’s defense against extracellular pathogens by production of 
the cytokines IL-4, IL-5, and IL-13. IL-4 is vital for the switching to IgE production in B 
cells67 and IL-5 is important in the activation of eosinophils68. Interestingly, GATA-3 
suppresses Th1 development69.  
By stimulation with IL-6 and transforming growth factor-β (TGF-β), the IL-17-producing 
Th17 cell subset has been identified70,71. The need for TGF-β is debated, and studies have 
suggested that IL-1β is more important than TGF-β72. The transcription factor needed for 
Th17 cells is RORγt (the human ortholog is RORC). IL-17 is important in the defense against 
extracellular bacteria and fungi by recruitment of neutrophils to the site of infection73 and 
induction of antimicrobial peptides74. Th17 cells have also received attention regarding the 
induction of autoimmune disease in several models75. The inter-regulation between the Th 
subsets is further suggested by studies showing that the Th17 phenotype is suppressed by the 
Th1-inducing cytokines IFN-γ and IL-1276. 
Regulatory T cells (Tregs) are important in order to control inflammation and restore 
homeostasis. The phenomenon of cellular immunity was mentioned in the seventies77,78, and 
the presence of an inhibitory CD4+ T cell subset was identified almost 20 years ago79,80, but 
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the Treg field exploded following the identification of Treg development through activation 
of the transcription factor forkhead box P3 (FOXP3)81,82. Phenotypically, Tregs are identified 
by their high expression of CD25, and an expression of FOXP3 and CTLA-483. In Papers IV 
and V, we used dim and negative expression of CD127 as an alternative marker of FOXP384-
86. Tregs were the subset of T cells that received most attention in Papers III, IV, and V. 
This is due to the crucial role of Tregs in GVHD and pregnancy87-91. The Tregs can be 
divided into several categories depending on their origin and effector function (which has 
been excellently reviewed by Liston and Gray92). Briefly, Tregs can be generated directly in 
the thymus, whereas some of them are induced in the periphery under certain conditions. 
Functionally, Tregs can be divided into central Tregs and effector Tregs. The markers that 
can be used for identification of these subsets are thought to be the ones that are used for 
identification of conventional naïve and effector T cells. Activated Tregs have encountered 
their antigen and have less need for CCR7 and CD62L, while non-activated Tregs have 
higher expression of CCR7 and CD62L92,93. Upon TCR, CD28, and IL-2 stimulation, central 
Tregs will develop an effector phenotype and can have suppressive functions. Continuous 
TCR, CD28, and IL-2 stimulation is particularly important for Treg expansion and survival94-
96. Compared to conventional T cells, which can produce IL-2 and use it in an autocrine 
fashion, FOXP3 represses production of IL-2 by Tregs themselves97. TGF-β can be used to 
induce Tregs98, although whether TGF-β is absolutely required for homeostatic expansion of 
Tregs has been questioned99. There are several ways in which Tregs can reduce immune 
responses. IL-10 might perhaps be one of the most recognized ways for Tregs to exert 
immunosuppression, and it was one of the first to be identified100,101. IL-10 production does 
not occur exclusively in Tregs, but IL-10 production by Tregs is very important in 
maintaining tolerance102. Moreover, Tregs constitutively express CTLA-4 and this is crucial 
for their function103. Just like CD28, CTLA-4 binds to CD80/CD86 on APCs and through this 
interaction it can induce indoleamine-2,3-dioxygenase (IDO) in the APC104,105. Whether or 
not the binding to CTLA-4 on Tregs has an intrinsic effect on them is still under debate106. 
However, the effect on target cells appears to be enough for CTLA-4-mediated suppression. 
One mechanism of suppression that has received attention in recent years is the ability of 
CTLA-4 to reduce expression of the co-stimulatory molecules on APC103,107 through 
transendocytosis108. Tregs may also suppress immune responses by several other 
mechanisms, including lymphocyte-activating gene (LAG)-3109, CD39/CD73 
expression110,111, promotion of IL-10 and TGF-β production in dendritic cells112, and 
production of TGF-β113 or IL-35114 by the Tregs themselves. Interestingly, while 
conventional T cells that respond to self-antigens are terminated during thymic selection, part 
of the naturally occurring Treg repertoire is to respond to self-antigens (generation of Tregs 
with self recognition is referred to as agonist selection)115. These Tregs are then dependent on 
continuous TCR activation to maintain functionality116. 
Following on from this introduction to the different T cell subsets investigated in Papers I‒
V, Figure 2 shows the characterization pattern we used to identify the T cells. Tregs were 
identified from high expression of CD25 and from FOXP3 expression in in vitro studies, and 
from the low CD127 expression in in vivo studies. Th1, Th2, and Th17 cells were identified 
from the expression of the surface chemokine receptors CXCR3, CCR4, and CCR690,117,118. 
The expression of these markers had previously been shown to be specific for CD4+ T cells 
with a cytokine profile associated with that specific T cell subset. In Paper V, we confirmed 
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that identification of the T cell subsets through expression of CXCR3, CCR4, and CCR6 will 
result in an enrichment of T cells with an expression of the transcription factor associated 
with each subset.     
  
1.1.1.5 Interleukin-2 and its receptor 
IL-2 has already been mentioned as an important cytokine for Tregs. IL-2 was first described 
in 197638, and was later shown to be a pivotal component of T cell growth and proliferation 
39,119-123. After TCR and co-stimulation through, for example CD28, IL-2 is regarded as one 
of the most important factors in T cell activation. IL-2 is important in regulating activation-
induced cell death124. IL-2 is produced by CD4+ T cells125,126 and to a lesser extent by CD8+ 
T cells, by NKT cells127, and by dendritic cells128. IL-2 was the first cytokine to be isolated129, 
produced130,131, and used as immunotherapy against cancer132. 
The IL-2 receptor (IL-2R) consists of three subunits: IL-2Rα, IL-2Rβ, and IL-2Rγc. The IL-
2R with all three subunits has a high affinity for IL-2. This high-affinity IL-2R is assembled 
upon initial binding of IL-2 to IL-2Rα133,134. This is followed by the interaction with the β and 
γc chains135. On the surface of the T cell, these three subunits are located in lipid rafts136,137. 
This enables assembly of the high-affinity complex after the initial binding. Once the high-
affinity receptor with ligand is formed, there can be a heterodimerization of the cytoplasmic 
domains on the β and γc chains. Consequently, downstream signaling is initiated by the Janus 
family of tyrosine kinases, JAK1 and JAK3138-140. As a control mechanism, activation of IL-
2R will subsequently lead to endocytosis of the receptor complex. The β and γc chains and 
IL-2 are degraded and IL-2Rα is recycled to the cell surface141. 
Signaling upon activation of the IL-2R will initiate several signaling pathways. They can be 
divided into three pathways that have been identified: the JAK/signal transducer and activator 
of transcription (STAT) pathway, the phosphoinositide 3-kinase (PI3K) pathway, and the 
RAS-mitogen-activated protein kinase (MAPK) pathway142. These pathways can in turn be 
regulated by TCR activation, for example143. In Paper IV, we determined the activation of T 
cells by measuring the phosphorylation of the main STAT molecules activated by IL-2, 
STAT5a, and STAT5b. However, STAT3 may also be phosphorylated by JAK1 and JAK3, 
which are present on the β and γc subunits, respectively144,145. The PI3K pathway is 
particularly interesting, since its downstream signaling can to some extent be suppressed by 
immunosuppressive drugs such as cyclosporine A (CyA)146 and sirolimus (SRL)147,148. A 
Th1$ Th2$ Th17$ Treg$
Transcrip.*
factor 
T.bet* GATA.3* RORC* FOXP3*
CD45RA$ 0$ 0$ 0$
CCR4$ 0$ +$ +$
CXCR3$ +$ 0$ 0$
CCR6$ 0$ 0$ +$
CD25$ ++$
CD127$ Dim/0$
Figure 2. CD4+ T cell subsets and the 
markers used to identify them in this thesis. 
This classification is based on the work of 
Acosta-Rodriguez et al.90. Except for the 
profile presented in the figure, the cells should 
have a lymphocyte phenotype according to the 
forward-scatter area (FSC-A) and side-scatter 
area (SSC-A) filters in a flow cytometer. The 
cells must also show positive staining with 
anti-CD3 antibodies and anti-CD4 antibodies, 
and negative staining with the viability dye 
7AAD.  
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summary of these pathways with the aim to improve understanding of the work in Paper IV 
is presented in Figure 3. The full pathway networks regarding TCR and interleukin signaling 
can be seen on the National Cancer Institutes Pathway Interaction Database website 
(http://pid.nci.nih.gov).  
Figure 3. Schematic diagram of the major signaling checkpoints upon activation of the high-affinity IL-2R, in 
order to explain the molecules discussed in this thesis (linked with black arrows). Note that almost all of the 
checkpoints have several downstream and upstream regulators that are not illustrated (gray dashed arrows). For 
instance, Sirolimus does not block the entire downstream signaling upon TCR- and IL-2R-mediated activation. 
TCR activation initiates multiple signaling cascades, including PI3K, which is shared with and amplified by IL-
2R signaling.  	  	  	  
1.1.2 History and concept of HSCT 
In the shadow of the atomic age, researchers began to develop strategies for counteracting the 
effects of radiation. Hematopoiesis is especially sensitive to radiation. The research initiated 
had the goal of replacing sick blood-forming cells with healthy hematopoietic stem cells149-
151. Luckily, an atomic war has never started, and research regarding hematopoietic stem cell 
transplantation has saved hundreds of thousands of lives in patients with conditions such as 
leukemia, aplastic anemia and inborn errors of metabolism.  
Before the concept of HSCT was established, induction of temporary remission in leukemia 
patients was achievable152, but a diagnosis of leukemia was still regarded as a death sentence. 
Nowadays, complete remission in patients with leukemia is often achievable without 
transplantation, but allogeneic HSCT is still the only potentially curative treatment. 
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Autologous HSCT using the patients own HSCs was successfully achieved in the 1950s153. 
However, patients suffering from leukemia may need bone marrow from another individual 
to replace the sick bone marrow. Thus, the pioneer E. D. Thomas transplanted six leukemic 
patients with allogeneic bone marrow in 1957, after total body irradiation154. However, 
improvements were needed in order for the allogeneic transplant to be successful. One major 
obstacle in allogeneic transplantation compared to the autologous setting is the MHC 
incompatibility between different individuals. Appropriately for this thesis, the idea of an 
HLA system originated to some extent from the study of feto-maternal tolerance, where 
maternal antibodies to paternal antigens were detected155. Following identification of the 
HLA system156, it was observed in dogs that matching of the donor and the recipient 
according to their MHC type before allogeneic HSCT improved the outcome157. But despite 
matching of the donor and the recipient, a graft-versus-host reaction still occurred whereby 
the immune cells of the donor attacked the tissues of the recipient. One way of managing 
GVHD was to use methotrexate158. It could then be shown that HSCT might be a successful 
treatment in patients with leukemia159,160. Survival rates following HSCT were increased 
further by the introduction of immunosuppressive drugs such as CyA161,162.       
Briefly, the procedure for modern allogeneic HSCT is as follows. First, the patient undergoes 
a conditioning regimen. The purpose of the conditioning regimen is to remove as many of the 
leukemic cells as possible, and to make physical and immunological space for the graft. The 
conditioning regimen usually consists of cytotoxic drugs and irradiation, but varies depending 
on the patient characteristics. There are two main types of conditioning: myeloablative 
conditioning (MAC)163,164 and reduced-intensity conditioning (RIC)165,166. Myeloablative 
conditioning is defined as a conditioning where the patient’s entire hematopoiesis is 
completely eradicated, without a transplant the patient will die. Reduced-intensity 
conditioning is, as it implies, a conditioning regimen where the patient (in theory) does not 
need a new transplant to survive. RIC was established in order to treat patient groups that 
would not survive MAC. Following the conditioning, the patient is neutropenic and very 
susceptible to infections. The next step is transplantation. An allogeneic graft is infused into 
the patient through an intravenous line. The graft is selected in advance to match the recipient 
as well as possible with regard to MHC genotype. Today, the alleles investigated for 
matching are HLA-A, -B, -C, -DP, -DQ, and -DR167.  
There are three different types of stem cell grafts: bone marrow (BM), peripheral blood stem 
cells (PBSCs; the stem cells are mobilized from bone marrow with granulocyte-colony 
stimulating factor168,169), and cord blood (CB). A graft from PBSCs or BM is preferred, but if 
there are difficulties in finding a well-matched BM or PBSC graft, a CB graft may be used. 
CB grafts require less MHC matching than BM and PBSC grafts due to the naïve nature of 
the graft170, but the number of HSCs is generally lower. After the transplantation, the patient 
is still neutropenic and must be in isolation, either in the ward or at home171. Initially, people 
were treated in sterile environments, in so-called laminar airflow rooms172. Adoptive transfer 
of immune cells with the graft can help to some extent in fighting infections after 
transplantation. It will take approximately two to three weeks for the graft to re-populate the 
bone marrow and to start producing new immune cells. The myeloid lineage will reconstitute 
faster than the adaptive immune system173,174. Two years after HSCT, the adaptive immune 
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system has still not fully reconstituted175. A schematic diagram of the transplant procedure is 
presented in Figure 4. 
There are several tasks that must be completed after HSCT in order for the patient to survive 
in the long term. The graft must populate the BM and restore hematopoiesis, infections must 
be controlled, and the remaining leukemic cells must be eradicated without letting the GVHD 
get out of hand. Despite conditioning, the graft may be rejected or undergo graft failure due 
to unsuccessful initial engraftment or loss of donor cells following initial engraftment. 
Recipient T cells, NK cells, or antibodies may cause this rejection. Increased mismatch of 
graft, UC grafts, and RIC are all major factors that increase the probability of graft failure and 
rejection176. If the graft is successfully engrafted, the patient may still undergo relapse later 
on. An allogeneic transplant, however, reduces the incidence of relapse significantly 
compared to an autologous transplant.  
One of the great advantages of allogeneic HSCT is the graft-versus-leukemia effect (GVL)177. 
The concept of GVL is that allogeneic cells from the graft recognize the leukemic cells and 
eradicate them. The allogeneic immune cell from the graft will recognize both healthy 
recipient tissue and the leukemic cells, but hopefully the leukemic cells will be better at 
triggering an adaptive immune response than the healthy tissue, and the GVL effect will 
therefore be stronger than the GVHD. GVHD occurs when the adaptive immune cells from 
the donor attack the recipient’s healthy tissues, and it will be discussed later in this thesis. But 
it is important to note here that to this date, GVHD and GVL cannot be differentiated from 
each other in clinical practice, and the balance between a potent GVL effect and not letting 
the GVHD get out of control is one of the most difficult parts of the post-transplant treatment 
of a patient. There have been reports of successful differentiation between GVHD and GVL 
using experimental animal models178. The conventional ways of managing GVHD and GVL 
are through the management of immunosuppressive drugs, graft composition, and the use of 
antibodies or additional transfer of immune cells. Using a graft that contains mature immune 
cells will be beneficial for management of infections and for maintenance of GVL, but it will 
cause more GVHD. It may differ between transplant centers whether or not the graft is 
depleted of immune cells before transplant179. Depletion of T cells is usually performed with 
anti-thymocyte globulin (ATG)180.  
The patient is closely monitored after transplantation in order to detect relapse. If the patient 
has increased blood levels of cells of recipient origin, which may be a sign of relapse, he or 
she may receive a donor lymphocyte infusion (DLI)181. A DLI contains graft and mature 
immune cells that can boost engraftment and mount an adaptive immune response against the 
recipient. The GVL and GVHD effect will therefore be enhanced. The possibility of giving 
DLI, if there appears to be a relapse, is a great advantage, and this is possible when BM or 
PBSCs are used as a source of graft. Due to the small quantity, CB grafts do not usually allow 
the possibility of DLI. As if handling of GVHD and prevention of relapse was not enough, 
one major problem after HSCT is infections. Since the patient suffers from a lack of cytotoxic 
lymphocytes following transplantation, even opportunistic infections are common 
complications. This includes viruses such as herpesviruses (cytomegalovirus, Epstein-Barr 
virus, and varicella-zoster virus)182, but also fungal infections (e.g. Candida and 
Asperigillus)183 and infections with bacteria from the commensal flora184. The occurrence of 
infections follows the immune reconstitution and immunosuppressive treatment of the 
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patient. Bacterial infections remain a problem until the physical barriers and the innate 
immune system have recovered. Fungal infections are common during the first six months 
after HCST. Clearance of viral infections is dependent on a fully functional adaptive immune 
system, and there can be recurrence even a year after transplantation. Compared to organ 
transplantation where immunosuppression is needed for the remainder of the patient’s life, 
HSCT grafts often develop tolerance and immune suppression is generally discontinued 
within a year after tansplant185.   
Figure 4. A schematic presentation of the main elements of allogeneic hematopoietic stem cell transplantation 
and common complications following transplant, including opportunistic infections, graft failure, and graft-
versus-host disease (GVHD). Abbreviations: RIC, reduced-intensity conditioning; MAC, myeloablative 
conditioning; PBSCs, peripheral blood stem cells; BM, bone marrow; UCSCs, umbilical cord stem cells.  
 
1.1.3 Graft-versus-host disease 
As mentioned, the balance between GVHD and GVL is crucial for a successful HSCT. Since 
GVHD and GVL are currently not differentiable in the clinical setting, GVHD reduces the 
occurrence of relapse186. However, some studies have shown that DLI may induce the GVL 
effect without inducing GVHD187,188. Thus, mild GVHD may be desirable in order to reduce 
the incidence of relapse, while a more severe GVHD is a terrible complication and must be 
avoided. This is not easy, especially when GVHD becomes resistant to therapy.  
GVHD was originally referred to as runt disease189,190, and was described early in the field of 
transplantation. In fact, the early work regarding GVHD is still very important in daily 
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clinical work, as the conventional clinical grading of the acute manifestations of the disease 
originates from the work by Glucksberg et al in 1974191. Despite the efforts of the research 
community and technological advancements, GVHD is difficult to diagnose and there are no 
objective GVHD-specific biological parameters that can be used to assess the severity of 
disease. By going through the pathophysiology, we can gain an understanding of the 
complexity of the disease and the difficulty in diagnosis and treatment of GVHD. 
GVHD can be broadly divided into two distinct pathophysiologies, acute GVHD (aGVHD) 
and chronic GVHD (cGVHD). This thesis focuses on acute GVHD. After this section, acute 
GVHD is the condition being referred to if not stated otherwise.  
Chronic GVHD usually occurs later than 100 days after transplantation. Although cGVHD 
reduces the risk of relapse, cGVHD is associated with morbidity and mortality192. The 
pathophysiology of cGVHD resembles that of autoimmune disorders193-195 such as sicca, 
scleroderma, primary biliary cirrhosis, wasting, and bronchiolitis obliterans.  
Acute GVHD commonly arises within 100 days of HSCT. The organs most commonly 
affected by aGVHD are the skin, intestine, and liver. aGVHD can be divided into four grades 
of severity: I‒IV, where grade IV is the most severe form and is associated with a very high 
mortality rate196. Grade I only includes skin involvement, while higher grades include 
gastrointestinal (GI) GVHD and/or liver GVHD191.  
The pathophysiology of GVHD can be divided into three important steps. This is theorized in 
a review by Ferrara59 with inspiration from “the danger model” presented earlier by 
Matzinger197. Briefly, the danger model discusses self and non-self recognition in the 
presence of a highly inflammatory environment, and proposes that stimuli associated with 
damage are more important than actual recognition of self and non-self. This concept is 
especially applicable to the field of autoimmunity.  
The first step of GVHD is initiated by the conditioning regimen. Chemotherapy and 
irradiation are blunt weapons to counter cancer cells, and will disturb nucleotide production 
and induce DNA damage in all cells in the body. The highly proliferative cells are hit hardest 
(e.g. epithelium of skin and GI tract). The tissue damage induced by the conditioning regimen 
will cause release of proinflammatory cytokines such as TNF-α198 and IL-159. Additionally, 
the reduced integrity of physical barriers will increase the presence of pathogen-associated 
molecular patterns199 (e.g. lipopolysaccharides from bacteria). All these factors contribute to 
the activation of APCs. This is a recipe for GVHD. Activated APCs will migrate from the 
tissue to a nearby secondary lymphoid organ and present self-peptides. After HSCT, donor T 
cells from the graft will scout the surface of the host-activated APCs. Following immune 
reconstitution, activated donor APCs will also present recipient peptides. This leads to the 
second step in GVHD pathophysiology; a direct or indirect allorecognition by the donor T 
cell. The proinflammatory milieu described above will augment this, and all the co-
stimulatory factors needed for a potent T cell response are present. Upon allorecognition, the 
T cells will expand and differentiate to effector lineages. It is mainly towards this step that the 
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prophylaxis against GVHD is targeted. For the last decades, the gold standard for 
immunosuppression in HSCT has been CyA combined with methotrexate200. Also, T cell 
depletion in vivo (ATG) or ex vivo can be used to prevent GVHD201. It is important to use 
drugs that target the IL-2 pathway prophylactically since if the cells are allowed to expand, 
they may still be able to perform effector functions later. There have been studies performed 
where the use of drugs that target IL-2 has been questioned regarding their impairment of 
Tregs, which are especially dependent on IL-2. In mice, Tregs have been shown to reduce 
GVHD while preserving the GVL effect202. Moreover, one study suggested that TNF-α and 
not IL-1 was of importance for the GVL effect in an experimental model203.  In another study, 
the same group showed that CyA but not SRL inhibited Tregs that are important in the 
reduction of GVHD204. There is also increasing evidence in clinical trials that SRL used as 
GVHD prophylaxis is associated with more Tregs205. Moreover, one approach to prevention 
of GVHD is an adoptive transfer of Tregs; this was described in 2011. Even though GVHD 
was reduced in the group of patients who received Tregs with their UC transplant, it had no 
impact on survival206. Apart from IL-2, other cytokines have been reported to be elevated in 
GVHD, for instance IFN-γ207, IL-6208, IL-8209, and IP-10210.  
The last step in GVHD pathophysiology is the effector function of CD8+ T cells, causing 
further tissue damage211. Also, NK cells have a role in GVHD as well as in GVL212. The 
potency of the response will depend on the tissue damage, the disparity in major and minor 
histocompatibility antigens, and the use of immunosuppressive drugs/T cell depletion to 
prevent priming of an adaptive effector response.  
As stated earlier, a clinical evaluation using the Glucksberg criteria is still the conventional 
method for diagnosis of GVHD, but finding objective biological parameters in order to 
improve diagnosis and prediction of GVHD is the subject of intensive research. There is a 
wide range of different biological factors whose expression has been shown to be elevated or 
downregulated in GVHD. These are involved in all categories of GVHD pathophysiology, 
including tissue damage and repair213, cell trafficking214,215, pro- and anti-inflammatory 
cytokines215, T cell function, and clonality216. The molecules that have received most 
attention in recent years are regenerating islet-derived-3-α (Reg3α, GI-GVHD)217,218, 
suppression of tumorgenicity 2 (ST2)219, and elafin (skin GVHD)220. Some of these soluble 
factors have been implemented in a model with the aim of correctly predicting the severity of 
GVHD221. These findings are limited, however, since the studies came from the same group 
and the reproducibility has so far been low (Uzunel, unpublished data) or debatable222.  
Despite efforts to prevent severe GVHD, it is still a common complication following HSCT. 
The conventional treatment for GVHD is corticosteroids223,224. However, treatment with 
steroids is not always sufficient, especially when the GVHD becomes refractory225. 
Unfortunately, there are no other conventional treatments for steroid-refractory GVHD. 
Immunosuppressive drugs such as CyA and SRL have been shown to be successful in 
prevention of GVHD, but they have limited efficacy for reduction of GVHD. The many 
different secondary treatments reflect the complexity of the disease, as each one targets a 
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wide variety of known GVHD symptoms. Some of the therapies that have been suggested or 
performed with some success include Psoralen and irradiation with ultraviolet A (Puva) 
226,227, intravenous immunoglobulin228, adoptive NKT or Treg therapy229, mesenchymal 
stromal cells230-232, decidual stromal cells233, and a variety of checkpoint inhibitors234 (e.g. 
SRL, MMF, ATG, and Ruxolitinib235). 
Recent progress regarding innate lymphoid cell (ILC) biology in GVHD has also shown that 
ILCs of subtype 3 (RORC as master regulator) that produce IL-22 may be of importance for 
the prevention of GVHD236,237. IL-22 has been shown to increase the function of gut 
epithelial stem cells, speeding up the regeneration of the intestine following conditioning236. 
This is an interesting approach, since it builds on removal of danger signals, which have been 
theorized as the first part of GVHD pathophysiology. There is a clinical trial aimed at 
investigation of whether therapy with IL-22 can reduce severe GVHD (ClinicalTrials.gov 
identifier number: NCT02406651). 
 
1.2 THE FETO-MATERNAL INTERFACE AND FETO-MATERNAL TOLERANCE 
Reduction of maternal immune responses to fetal tissues is key to a successful pregnancy238. 
In this section, I will briefly discuss some of the mechanisms that may be of importance for 
feto-maternal tolerance.  
The concept of acquired immunological tolerance during pregnancy was first described by 
Medawar in the early 1950s239. Although much research has been performed in the field, the 
mechanisms known today are still insufficient to give a complete picture. Also, most of the 
research has been performed in experimental models―which do not necessarily reflect feto-
maternal tolerance in man240.  
Placentation will not be covered since it is outside the scope of this thesis (but for those 
interested, see review by Moffett241), and we will instead move to the structure of the placenta 
and adjacent tissues at the end of gestation. The sites at which the fetal and maternal tissues 
and cells are in contact are referred to as the feto-maternal interface. The feto-maternal 
interface can be divided into two compartments. First, there is the contact between the 
maternal decidua, which is derived from the endometrium, and the outer layers of the 
placenta. The outer layers of the placenta are the chorionic plate and the chorionic membrane. 
Depending on whether the decidua are in contact with the site of implantation or the fetal 
membranes, its is referred to as the decidua basalis or the decidua parietalis, respectively. The 
second feto-maternal interface is where the maternal blood infiltrates the vascularized 
placental body and interacts with the fetal trophoblasts that reside there. A schematic diagram 
of the structure of the feto-maternal interface is presented in Figure 5.  
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Figure 5. The structure of the placenta and its adjacent tissues.  
An interesting thought would be to regard the placenta as a haploidentical transplant. 
However, transplantation of a solid organ or hematopoietic stem cells will lead to rejection 
by/of the host, while pregnancy is tolerated. Thus, there must be fundamental differences in 
these two entities in the priming and effector responses of the immune system to non-self. As 
mentioned, acute rejection is driven by direct and indirect allo-recognition. Donor or recipient 
tissue-resident APCs will collect graft antigens and migrate to proximal lymphoid organs. 
Presentation of a foreign peptide to a T cell by a foreign APC (direct allorecognition) will 
elicit a stronger response in a larger quantity of T cell clones than if a foreign peptide is 
presented by self APCs (indirect allorecognition). Interestingly, studies have indicated that 
indirect allorecognition―and not direct allorecognition―is the major pathway for the 
maternal immune system to recognize fetal antigens242,243. The reason for this may depend on 
a few already identified factors. First, trophoblasts have no expression of MHC class II 
molecules, limiting priming of CD4+ T cells in the placenta241. The trophoblasts also have an 
unusual expression of HLA-C, HLA-G, and HLA-E, while expression of the highly 
polymorphic HLA-A and HLA-B is limited. In addition, the dendritic cells that are resident in 
the decidua are restricted in their ability to leave the tissue and migrate to the lymph nodes244, 
with a reduced transcription level for the RNA encoding chemokine CCL21, one of the 
ligands for CCR7. Another explanation could be the absence of lymphatics in the decidua245, 
limiting the possibility of primed DCs to migrate to lymphoid organs. This does not rule out 
the possibility of fetal-derived peptides reaching the lymph nodes and being taken up by 
APCs resident in the lymph node, but the priming of the T cells will be less effective without 
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the help of APCs that have migrated from the tissues. As if limitation of DC migration for 
efficient T cell priming was not enough, studies have suggested that gene silencing in the 
decidua prevent migration of effector T cells to the feto-maternal interface246. Specifically, 
upon activation by TNF-α, myometrium upregulates the levels of transcription for RNAs 
encoding Ccl5, Cxcl9, and Cxcl11 whereas stromal cells from decidua do not. The 
chemokines produced by these transcripts are ligands for CXCR3, which is present on Th1 
cells. Altogether, the results of these studies indicate that one way of maintaining feto-
maternal tolerance is to limit the allorecognition and reduce infiltration of effector T cells.  
Despite the factors mentioned above, immune cells are present at the feto-maternal interface, 
but the composition differs from that in the non-pregnant state. A pregnancy-specific subtype 
of decidual NK (dNK) cells is abundant in the decidua and plays a pivotal role in the 
intravascular trophoblast invasion of the uterus. This cell population represents a major part 
of the total lymphocyte population in the uterine compartment. The number of cells is 
reduced at term relative to the early stages of pregnancy, and they are phenotypically 
different from NK cells in peripheral blood247. Also, the cytotoxic ability of dNK cells is 
reduced by recognition of HLA-E expressed on trophoblasts248,249. Instead, dNK cells have 
secretory functions, and produce for example IFN-γ, IL-8, and TNFα247. Together with 
macrophages, dNK cells can contribute to the induction of Tregs250.  
Macrophages in the decidua are a fairly large proportion of the leukocytes located there. 
Macrophages are tissue-resident phagocytes that are potent in clearing the extracellular space 
from apoptotic cells, bacteria, and debris. They originate from monocytes that differentiate 
when stimulated and migrate to the tissues. Macrophages are potent APCs. Like T cells, 
macrophages can be divided into specific lineages. They were previously designated M1 or 
M2(a,b,c) macrophages, depending on whether they have a Th1 or a Th2 immune function 
and differentiation profile. The nomenclature regarding these lineages can be based on the 
conditions in which isolated monocytes differentiate251. Human monocytes cultivated in 
colony stimulating factor-1 (CSF-1), also named M-CSF, differentiate into macrophages. 
Additions to the culture may give macrophages with a specific profile. The factors commonly 
used are LPS, IFN-γ, glucocorticoids (GCs), ICs, TGF-β, IL-10, and IL-4. The subtypes 
produced can consequently be referred to as M(IL-4), M(ICs), M(IL-10), M(GC+TGF-β), 
M(GC), M(LPS), M(LPS+IFN-γ), and M(IFN-γ). The latter three fall into the commonly 
referred to M1 spectrum of macrophages, while the others can be placed in the M2 spectrum. 
Phenotypically, decidual macrophages fall close to M(IL-10), as decidual macrophages that 
spontaneously produce IL-10 have been found to be enriched compared to 
monocytes/macrophages in peripheral blood252. In the same study, there was no difference in 
the secretory patterns of IL-4 and IFN-γ between decidual macrophages and 
monocytes/macrophages in peripheral blood. Others have shown that M-CSF and IL-10 are 
the two most important factors for driving the differentiation of monocytes towards 
macrophages with a gene expression profile similar to ex vivo separated decidual 
macrophages253. Interestingly, decidual macrophages are highly functional phagocytes and 
are therefore potentially potent APCs254. In contrast, decidual macrophages have low 
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expression of the co-stimulatory molecule CD86255, which is important for a sufficient T cell 
activation. Indeed, decidual macrophages are more potent than macrophages from peripheral 
blood in suppressing alloreactive PBMCs256. In addition, studies have suggested that decidual 
macrophages can suppress Th1 effector functions and induce Tregs through their expression 
of PD-L1, IL-10, IDO257, and TGF-β258. IDO is an enzyme that depletes tryptophan in the 
microenvironment, causing T cells to undergo cell-cycle arrest. The metabolites from 
tryptophan degradation have also been seen to render Th1 rather than Th2 cells sensitive to 
apoptosis259. Altogether, these data suggest that decidual macrophages have the ability to 
maintain homeostasis through phagocytosis and to contribute to a tolerogenic niche at the 
feto-maternal interface.  
T cells are also important in feto-maternal tolerance. Compared to the NK and macrophage 
compartment, the number of T cells in the feto-maternal interface is low260. Compared to 
peripheral blood, where the T cell compartment contains more CD4+ cells than CD8+ cells, 
the feto-maternal interface mainly contains CD8+ T cells. A recent study has shown that 
there is an accumulation of virus-specific TEM CD8+ T cells in the decidua during 
uncomplicated pregnancy, which may suggest that the skewing of the CD8+ T cell 
compartment may be due to management of infections rather than allogeneic responses 
against fetal tissue261. Tregs are also enriched at the feto-maternal interface90,262, but not in 
peripheral blood during pregnancy263. Th1 cells are more abundant in the decidua, while Th2 
and Th17 ratios are lower compared to peripheral blood90. This is in line with the high 
number of CD8+ T cells, where Th1 cells may be important for enhancement of the 
probability of activation of the CD8+ cells, while Tregs support tolerance of the fetus. 
Induction of Tregs at the feto-maternal interface has been linked to activity through the IDO 
and PD-L1 pathways242,264. One experimental study has shown that IL-10 is not necessarily 
needed for successful pregnancy265. This may suggest that other immunosuppressive 
functions of Tregs (see above) may have a greater influence on feto-maternal tolerance. The 
presence of Tregs is, however, still important for a successful pregnancy. It has been shown 
that miscarriage and pre-eclampsia are associated with reduced levels of Tregs266.    
Another cell type that has been shown to be of importance in maintaining tolerance is the 
decidual stromal cell. I will continually discuss DSCs and their immunosuppressive 
functions―and consequently, their role in feto-maternal tolerance―throughout the remainder 
of this thesis, based on the theory that some of the properties of DSC-mediated immune 
suppression can be translated in adoptive DSC therapy in order to restore homeostasis in 
patients with GVHD.  
 
1.3 STROMAL CELLS 
Stromal cells are crucial for maintenance of the extracellular space and preservation of the 
structure of connective tissue. Depending on their localization, they have different specialized 
assignments. In this thesis, I will focus on decidual stromal cells (DSCs) and their 
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immunoregulatory properties, as well as the properties that are important for isolation and in 
vitro expansion. Indeed, the role of stromal cells in immunity is diverse, ranging from 
creation and maintenance of the bone marrow niche267, development of adaptive immune 
responses in lymphoid tissue268, maintenance of mucosal homeostasis269, feto-maternal 
tolerance270, and induction of immune privilege close to tumors271. A large part of the 
literature available is focused on mesenchymal stromal cells (MSCs), mostly isolated from 
the bone marrow (unless otherwise stated, the term MSCs always refers to bone marrow-
derived MSCs).  Some of the differences between DSCs and MSCs have been elucidated in 
the Results and Discussion sections of Papers I‒V, and these two subsets will therefore be 
introduced in most depth. When mentioned and discussed, the term “stromal cells” alone is 
used to refer to all stromal cells, including DSCs and MSCs, and it also applies to studies 
where there is confusion regarding the origin of the stromal cells.   
 
1.3.1 Characterization 
Stromal cells can be isolated from many different compartments of the placenta and its 
adjacent tissues, including amniotic fluid272, decidua basalis, decidua parietalis273,274, 
chorionic villi275, umbilical cord276, amnion and chorion277. MSCs can also be isolated from a 
wide variety of other connective tissues, but isolation from bone marrow is most common267. 
In the initial study comparing the different types of MSCs isolated from placenta, despite the 
fact that stromal cells are a heterogeneous cell type, these stromal cells appeared to have 
some similarities274. These features are also the ones that are used to identify MSCs in 
general. First, stromal cells usually have differentiation capability in vitro towards 
mesodermal cell types such as bone, fat, and cartilage278. Stromal cells from the placenta have 
been shown to be able to differentiate to other lineages as well, for instance neuroglia279, 
hepatocytes280, and skeletal muscle cells281. This is consistent with the broad function and in 
vivo distribution of stromal cells. However, there have also been studies showing that some 
stromal cells have limited differentiation ability273. Especially when isolating stromal cells 
from placental tissue, it may be important to test the origin of the cells, since they may be of 
maternal or fetal origin282. Moreover, MSCs show positive expression of CD73, CD90, and 
CD105283. The cells also lack expression of markers indicating endothelial, myeloid, and 
hematopoietic lineage. Normally, MSCs do not have any expression of HLA-DR, but this can 
be induced by IFN-γ284. In vitro, the cells adhere to plastic under normal culture conditions. 
After initial seeding, the cells proliferate and form colony-forming units283. The 
characteristics of the DSCs that we isolated and described in Papers I‒V will be discussed 
further later on.    
 
1.3.2 Stromal cell-mediated immune modulation 
Perhaps one of the features of MSCs that initiated an extensive exploration of their 
immunomodulatory properties was when these cells were reported to inhibit activated T cells 
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in experimental models and in the human setting in vitro285-288. This is a feature that has been 
reported in many different types of stromal cells. This inhibition does not appear to be 
dependent on HLA matching. It was subsequently shown that MSCs could inhibit the 
generation and function of DCs (reduced expression of MHC class II, CD11c, and CD83), 
which can result in a reduced ability of DCs to activate an adaptive immune response289-291. 
Although they are considered to have immunosuppressive properties and to be 
immunoprivileged, MSCs can promote proliferation of unstimulated peripheral blood 
mononuclear cells (PBMCs) to some extent288, as well as activate the complement system292.  
Furthermore, MSCs have been associated with a variety of immunomodulatory factors, which 
is consistent with the idea of being a supportive cell type with the role of maintaining 
homeostasis in the tissue of residence. The immune modulation by stromal cells may be 
broadly divided into three categories: direct or indirect immune suppression, APC ability, and 
anti-apoptotic/other supportive functions.  
No definitive pathway for stromal cell-mediated immunosuppression has yet been identified. 
However, one interesting feature is that many of the suggested pathways of immune 
suppression by stromal cells is initiated when the cells are primed by cytokines (e.g. IFN-γ, 
IL-1α/β, and/or TNF-α)291 or engagement of toll-like receptors (TLR-3). IDO is upregulated 
by IFN-γ/TNF-α in stromal cells and has been reported to induce a switch towards 
macrophages with phenotype within the M2 spectrum (possibly M(IL-10))293 and to suppress 
PBMCs by depletion of tryptophan294. Moreover, studies have also suggested that IDO 
production in stromal cells in part promote Tregs and inhibit Th17 differentiation295. This has 
also been seen in other cell types, such as macrophages258 and dendritic cells296 that produce 
IDO. Production of IDO is not exclusive for stromal cells, but appears to be more linked to 
the production of IFN-γ. Indeed, IDO production initiated by IFN-γ is suggested to be one 
explanation for why IFN-γ can be regarded as both a proinflammatory and an anti-
inflammatory cytokine. Another soluble factor that has been shown to be of importance for 
stromal cell-mediated suppression of adaptive immune cells is PGE2. Just like IDO, PGE2 
production is highly elevated in MSC cultures with added IFN-γ or TNFα297. By the addition 
of a competitive inhibitor to PGE2 (indomethacin), the antiproliferative effect of stimulated 
PBMCs in vitro was found to be abrogated297. Moreover, nitric oxide (NO) has also been 
shown to be a factor of importance for prevention of GVHD in mice by primed MSCs298. 
Many of these factors are soluble and do not require direct contact between the stromal cell 
and the target cell. NO is, however, quickly degraded. 
Aside from immunomodulatory effects that can be directly correlated to primed stromal cells, 
these cells have been shown to have constitutive expression of PD-L1, which can interact 
with PD-1 on lymphocytes and inhibit their activation36,299. A soluble factor, HLA-G5, has 
also been shown to be secreted by stromal cells300. HLA-G5 has a low polymorphism 
compared to other HLA class I molecules. Its known ligands are a specific NK-cell receptor 
(CD158d) and two leukocyte immunoglobulin-like receptors (CD85j and CD85d), which are 
expressed on myeloid cells and monocytes, DCs, and lymphocytes, respectively. 
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Interestingly, HLA-G is also expressed on cytotrophoblasts and may be of importance in feto-
maternal tolerance301. Blocking of soluble HLA-G5 in allo-stimulated cultures reduced the 
frequency of Tregs in one report300. Additional factors that have been implicated in stromal 
cell-mediated suppression of immune cells is secretion of galectins302 and exosomes 
containing suppressive factors (e.g. miRNA)303, expression of the adhesion markers ICAM-1 
and VCAM-1 to facilitate suppression304, and increased adenosine production through 
expression of CD39 and CD73305. As mentioned previously, prevention of migration of T 
cells by DSCs may also be one way of reducing immune responses at the feto-maternal 
interface246.  
As already described, many factors have been identified that mediate suppression of immune 
responses by stromal cells. However, stromal cells may also trigger immune responses. IFN-γ 
can increase expression of HLA class II molecules on MSCs306, which enables priming of 
adaptive immune responses284. Apart from from priming CD4+ T cells by HLA class II, 
stromal cells may also cross-present exogenous antigens to CD8+ T cells307. This can happen 
despite the fact that stromal cells do not normally express CD80/CD86 (also presented in 
Paper I).  
Lastly, stromal cells may have anti-apoptotic features. For instance, MSCs have been 
suggested to prolong the survival of T cells under co-culture. The expression of Fas ligand 
and CD95 is reduced when T cells are cultured with MSCs308.  
  
1.3.3 Stromal cell therapy 
The field regarding stromal cell-based therapy has literally exploded during the past ten years. 
As of October 2015, more than 550 clinical trials involving stromal cell-based therapy (with 
MSCs mainly) were registered at NIH (ClinicalTrials.gov). The range of application is wide, 
and includes GVHD, boosting of engraftment after HSCT, Crohn’s disease, type-1 diabetes, 
acute respiratory distress syndrome, and ischemic cardiomyopathy among others. All of these 
have shown effects of MSCs in preclinical models of the diseases267.  
MSCs were first introduced as a treatment for GVHD in 2004231. In that case study, severe 
GVHD was successfully reversed in a boy twice by intravenous infusion of 2 × 106 cells/kg 
and 1 × 106 cells/kg, respectively. Subsequent follow-up studies showed that MSCs may 
reduce GVHD230,232. Long-term survival in this patient group was not altered with stromal 
cell therapy309,310. Other studies in which MSCs have been used to treat GVHD are 
summarized in reviews by Kaipe311 and Luk312, with some exceptions of recently published 
studies222,310,313-315. To conclude, from the data that are currently available, it is difficult to 
determine whether treatment is efficient or not. This is based on the fact that there have been 
few randomized trials, that there have been mixed results in published studies, and that there 
was limited surveillance in the studies apart from clinical response. There is currently one 
ongoing phase-III academic study where the efficacy of MSCs is being evaluated in the 
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context of GVHD316. The cells used in these studies were mostly from a third party, meaning 
that the cells were not derived from the recipient or from the donor. The origin of the MSCs 
in the clinical setting is bone marrow, umbilical cord, or adipose tissue.  
Since MSCs have a role in creation of the bone marrow niche, one theory is that co-
transplantation of MSCs and HSCs might enhance engraftment and reconstitution. This was 
first performed in 2005317, where HLA-identical MSCs were co-infused with the graft. The 
outcome of this therapy varies. Co-transplantation was found to be associated with faster 
lymphocyte and platelet recovery318-320. A subsequent study by the same group showed that 
MSC co-infusion did not reduce the risk of graft failure but might reduce the risk of severe 
GVHD321. In umbilical cord transplants, data from our center have indicated that co-infusion 
of MSCs can be associated with an impaired adaptive immune reconstitution320,322. Other 
studies have suggested an increased rate of leukemic relapse323 and development of post-
transplant lymphoproliferative disease (PTLD)324.  
The fate of MSCs following infusion has not been fully elucidated. An experimental GVHD 
model has shown distribution of MSCs to the sites of inflammation325. Migration patterns of 
intravenously infused stromal cells in acute or chronic GVHD in man indicate limited 
homing or engraftment at sites of inflammation118,326. Interestingly, one study showed that the 
ability to home to bone marrow is reduced when the cells are cultured in vitro, compared to 
primary cells327. The way of administration may also affect in vivo distribution. For instance, 
intra-arterial administration in rabbits has a different distribution pattern compared to 
observations of intravenous infusion in man328. Factors such as survival of the cells may have 
a large influence on the in vivo distribution. Studies have indicated that MSCs are quickly 
attacked by the complement system upon administration, as seen in experimental models and 
in vitro292,329. 
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2 AIMS 
The general aims of the work for this thesis were to: 
• Investigate the immunoregulatory effects of decidual stromal cells isolated from term 
placentas in allogeneic settings in vitro, and to determine how these cells affect 
adaptive immunity.  
• Increase our understanding of how the immune system is affected by cellular therapy. 
The specific aims of Papers I‒V were to:  
Paper I 
• Isolate stromal cells from the fetal membranes, placental villi, umbilical cord, and 
bone marrow and to characterize the cells with regard to cell-surface expresssion of 
known stromal cell markers and integrins that have been shown to be of importance in 
MSC-mediated immune modulation.  
• Investigate the basic immunomodulatory properties of the different stromal cell 
populations in allogeneic settings in vitro.  
Paper II 
• Introduce the use of DSCs as cellular therapy for GVHD. 
• Further characterize DSCs used clinically regarding origin, cell-surface expression, 
and expansion potential. 
Paper III 
• Further investigate immunomodulatory effects of isolated DSCs, concentrating on 
parameters that are known to be of importance for feto-maternal tolerance and MSC-
mediated immunomodulation. 
• Provide a basis for further studies of isolated and expanded DSCs. 
Paper IV  
• Based on the findings in Paper III, further explore the ability of DSCs to modulate 
IL-2 production, IL-2R expression, and IL-2R signaling in alloantigen-stimulated T 
cells in vitro and in vivo.  
Paper V 
• Monitor immune parameters that have been shown to be of importance in GVHD and 
other inflammatory settings in patients following treatment with DSCs for GVHD.  
• Identify factors of importance that can be used to identify or predict response to 
treatment with DSCs, and gain a better understanding of how DSCs affect 
immunological parameters in vivo. 
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3 MATERIALS AND METHODS 
For the exact manufacturers of reagents, consumables, and hardware, please see each 
individual paper, as this may have varied slightly between papers. In the following section, 
the basic methodology of the techniques that were most used in Papers I‒V will be briefly 
described and discussed. The isolation of DSCs will be presented in more detail. 
 
3.1 ETHICAL CONSIDERATIONS 
Ethical approval for all the studies presented in this thesis was obtained from the regional 
ethics committee at Karolinska Institutet. This includes: isolation of mesenchymal stromal 
cells (DNR 446/00) and stromal cells from placenta (DNR 2009/418/31/4, 2010/2061-32). 
Clinical use of DSCs and follow-up of patients treated with DSCs was also approved (DNR 
2010-452-31/4, 2014/2132-32) by the same committee. All patients signed informed consent 
and were treated in accordance with the Declaration of Helsinki. 
 
3.2 ISOLATION AND EXPANSION OF STROMAL CELLS FROM PLACENTA 
One advantage of stromal cells isolated from placental tissue is that the cells are obtained 
from tissue that would otherwise be discarded directly after delivery. Prior to planned, 
uncomplicated caesarean section, the mothers sign informed consent to donate their 
placentas. After caesarean section, the placenta is placed in a sterile metal container and 
transferred to the laboratory where the isolation takes place. The metal container is directly 
placed in a class II laminar airflow cabinet. The isolation protocol was inspired by the 
isolation protocol of amniotic epithelia and mesenchymal cells by Ellis and Strom330,331. The 
DSCs were used in all the papers presented in this thesis.  
First, excess blood was washed away with phosphate-buffered saline (PBS). Then, the fetal 
membranes (containing amnion, chorion, and decidua parietalis) were dissected from the rest 
of the placental tissue. The cut in the membranes was made approximately 1 cm from the 
chorionic plate. This can be viewed in detail in Figure 6. The membrane was then cut into 3‒
4 pieces, placed in 50-ml falcon tubes, and washed another few times. This was followed by 
trypsination performed in four steps. First, the membranes were swirled in 10 ml 
trypsin/EDTA solution for 30 seconds. The trypsin digests were then discarded. Twenty-five 
ml fresh trypsin/EDTA was added and the tubes were incubated for 10 min at 37°C. The 
trypsin digest was discarded in this step also. Trypsin/EDTA was added a third time and was 
then incubated for 40 min. This step was repeated once. This yielded two products: the 
trypsin digests and the fetal membranes, which both contained DSCs. Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS), 100 U/ml 
penicillin, and 100 µg/ml streptomycin (hereon referred to as DMEMcomp), was added in the 
same volume as the trypsin/EDTA to inhibit the trypsin. The products were centrifuged and 
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washed twice in DMEMcomp. The cells in the trypsin digests were pooled, counted, and 
seeded in 185 cm2 flasks at a concentration of 105 cells/cm2. Four or five pieces of membrane 
were seeded in separate flasks. The total volume DMEMcomp in each flask was 20 ml. The 
medium was changed every 3‒4 days. The stromal cells migrate from the tissue explants and 
adhere to the bottom of the culture flask. When colony forming units (CFUs) had developed 
(after ≥ 10 days), the membrane pieces were removed and the cells were expanded until 90% 
confluency had been reached (in 25 ml DMEMcomp). The cells were subsequently harvested 
by depletion of DMEMcomp and addition of 4 ml trypsin/EDTA followed by washing in 
DMEMcomp. The DSCs were frozen in aliquots (in DMEMcomp supplemented with 10% 
dimethylsulfoxide (DMSO)) until use. The cells were then at passage 0. For expansion to 
higher passages, 0.5 × 106 DSCs were added to a 185 cm2 culture flask with 25 ml 
DMEMcomp (final volume). This was cultured as described above until 90% confluency was 
reached. This protocol was the same in all papers. Quality control and characterization of the 
DSCs will be presented in the Results section. The methods used were mixed lymphocyte 
reactions (MLRs) to investigate the immunosuppressive capacity of DSCs in the allogeneic 
setting, PCR to determine the origin of the cells, and flow cytometry (FC) for identification of 
cell-surface markers. Karyotyping and investigation of differentiation capabilities were also 
carried out, but not on DSCs from all donors.  
Figure 6. Schematic presentation of work flow for the isolation of decidual stromal cells from term placental 
tissue.  
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3.3 THE ALLOGENEIC SETTING IN VITRO 
Most of the in vitro work in Papers I‒IV regarding DSC-mediated immune modulation was 
based on the simple MLR. Briefly, PBMCs were obtained from buffy coats by Lymphoprep 
gradient centrifugation. The cells were washed twice in PBS and resuspended in RPMI 1640 
medium supplemented with 5‒10% human AB serum, 100 U/ml penicillin, 100 µg/ml 
streptomycin, and 2 mM L-glutamine (hereon referred to as RPMIcomp) at a concentration of 
3 × 106 cells/ml. These PBMCs were stimulated with the alloantigens from an irradiated pool 
of PBMCs from at least six donors. The ratio of responder cells to stimulator cells was 1:1. 
DSCs were added to these cultures, either directly in order to interact with the MLR through 
cell-cell contact, or in a transwell, which precluded cell contact-dependent interactions. The 
incubation period for the assay was normally 6 days. In addition to these standard conditions, 
a wide range of agents was added to these cultures. The DSCs may also have been pretreated 
with soluble factors before addition to the MLR. The readouts for this assay were 
proliferation by 3H-thymidine incorporation (Papers I‒IV), extracellular or intracellular 
phenotyping by FC (Papers I, III, and IV), determination of cytokine concentration by 
ELISA (Papers I, III, and IV) or by Luminex (Paper IV), and/or RNA expression by PCR 
(Paper IV).  
Although the assay is methodically straightforward, it has limitations―especially regarding 
the specificity of the parameter of investigation. The MLR contains all cells of the lymphoid 
lineage, as well as monocytes. This allows a biologically direct and indirect allorecognition. 
The impurity of the system also limits the reliability of specificity of an interaction, which 
may very well be the result of an intricate cascade involving many cell types. This was of 
particular interest in Papers I, III, and IV, where specific pathways were investigated. In 
Paper IV, one of the explanations for why the MLR was favored over other stimulation 
assays―for instance, the use of anti-CD3/CD28 antibodies on purified T cells or stimulation 
with DCs―was that the interaction under investigation was not detectable in the anti-
CD3/CD28 system due to the high level of T cell activation. 
Proliferation was measured using 3H-thymidine. Every time a cell divides, its genome is 
duplicated, which leads to incorporation of 3H-thymidine. Based on the level of proliferation, 
this is detected as an amplified signal relative to the control. This method measures the 
proliferation over the last 16‒24 h. An alternative technique for measurement of proliferation 
is CFSE staining, which is a dye that binds to the cell membrane and that is added to the cells 
before the incubation. This method has the advantage of showing the proliferation during the 
entire culture period. For every cell division, the dye will be diluted, theoretically halving the 
signal from the CFSE during FC analysis. However, in our hands the CFSE staining 
negatively affected both the proliferation characteristics and the phenotype of the activated T 
cells (Paper III, data not shown). We observed that the amount of activated T cells (CD25+) 
was systematically reduced when CFSE was used. Others have also found this332, but toxicity 
may be avoided with optimized concentrations of CFSE and addition of FCS to the labeling 
medium333. Results on proliferation in MLRs only labeled with CFSE are given in Paper I.  
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3.4 FLOW CYTOMETRY 
FC allows detection of cellular phenotype at the single-cell level. By using specific 
fluorochrome-conjugated antibodies, millions of cells with a very specific phenotype can be 
swiftly characterized. The instrument uses lasers, which hit droplets that have been preformed 
to contain a single cell stained with fluorchrome-conjugated antibodies. The emission 
spectrum for all the fluorochromes in each droplet is detected after the excitation. In Papers 
I‒V, FC was the most commonly used instrument of analysis. The major limitation of the 
method lies in the overlap in the emission spectra of the different fluorochromes used. The 
panels used in Papers I‒V had a maximum of nine colors. The number of parameters 
analyzed can be increased by using more recent technologies involving rare metals instead of 
fluorochromes334, or by determining multiple RNA expression intensities at the single-cell 
level335.  
The staining procedure is described in each paper (Papers I‒V). In the analysis, we used 
fluorescence minus-one controls (FMOs) to define the negative populations336,337. In high-
dimensional FC, this is the preferred type of control. The FMO controls were especially 
important in Papers IV and V, where the intensity of expression of some parameters was 
very low. In those parameters, FMO controls were the only reliable way of differentiating 
positively stained cells from unstained cells. This also limits the reliability of the results to 
some extent, especially when taking the increased autofluorescence on activated T cells into 
account. In Paper V, other limiting factors such as sample size also determined the outline of 
the panels. Intracellular staining reduces the antigen epitopes on the cells, making it difficult 
to combine intracellular staining with other markers. This increases the number of specimens 
needed for each sample. We therefore chose to characterize the common T cell subsets with 
surface markers instead of using intracellular staining of their signature transcription factors 
(Figure 2). This allowed further phenotyping, without compromising the number of events 
collected in each specimen. 
 
3.5 STATISTICAL ANALYSIS 
For Papers I‒IV, Wilcoxon matched-pair signed rank test was performed on related samples, 
whereas the Mann-Whitney U-test was used for continuous unrelated variables when 
comparing two groups.  
For Paper V, Fisher’s exact test was performed on non-parametric categorical data including 
two groups and two variables. Where additional parameters were included, Chi-square test 
was used. The D’Agostino and Pearson omnibus normality test was used to determine normal 
distribution. Since the patient data were related for each patient over time, Friedman’s test 
was used to compare all time points in each group (responder/non-responder/all patients) for 
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each parameter. The pairwise comparison that followed required Bonferroni adjustment to 
reduce the p-value for what was regarded as a significant finding.  
Orthogonal projection to latent structures by means of partial least-squares discriminant 
analysis (OPLS-DA) was used to find parameters that differed between the responders and 
the non-responders among the parameters assessed by FC and Luminex. This analysis scales 
all values for each parameter, calculates the difference between the groups, and presents the 
parameters of importance that discriminate the groups. The parameters of importance 
generated by the OPLS-DA were subsequently analyzed with the Mann-Whitney U-test.   
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4 RESULTS AND DISCUSSION 
4.1 ISOLATION, CHARACTERIZATION, AND EXPANSION OF DECIDUAL 
STROMAL CELLS 
MSCs have immunomodulatory properties and they have been used successfully as a cellular 
therapy against GVHD. However, various aspects of the protocol required improvement. For 
instance, isolation of the cells was invasive for the donor and the expansion potential of the 
cells was highly variable and depended on the donor. In order to establish a clinical therapy, it 
is of importance to be able to obtain the cells of interest easily, and to be able to expand them 
to numbers sufficient for efficient clinical therapy. The aim of Paper I was therefore to find 
stromal cells that were easily isolated and had potent immunosuppressive functions. Stromal 
cells from placental tissue have a crucial role in feto-maternal tolerance, and should therefore 
have immunomodulatory properties to sustain the fetal allograft during pregnancy238. Cells 
from placental tissue are easily obtained, since the placenta is normally discarded after 
delivery. Studies published before Paper I had indicated that stromal cells from the placenta 
could be isolated and that the cells had a comparatively great expansion potential274. These 
papers, however, lacked comparative functional and characterization data that would be of 
importance for possible implementation in cellular therapy. With the rationale of finding 
stromal cells of potential clinical interest, with comparable immunomodulatory properties to 
those of MSCs isolated from bone marrow, we isolated stromal cells from different parts of 
the term placenta. The sites from which stromal cells where isolated included the two feto-
maternal interfaces, the blood-bathed placental villi (PVSC) and the fetal membranes (DSCs 
are described as FMSCs in Paper I and as FMCs in Paper II). Additionally, stromal cells 
were isolated from Wharton’s jelly of the umbilical cord (UCSCs). The stromal cells from 
these three compartments were then characterized and compared to MSCs derived from the 
bone marrow. Morphologically, cells from all three sources are quite similar (Paper I), and 
have spindle-like fibroblast morphology (see Figure 6). Moreover, the expression of surface 
markers that are used to identify MSCs283 is the same when comparing the four sources 
(Paper I), and includes expression of CD29, CD73, CD90, and CD105. Moreover, of the 
markers that we investigated, we found that DSCs and MSCs also expressed CD44 and PD-
L1 (Paper I), and DSCs were positive for PD-L2 also (Paper II, Figure 7). Stromal cells 
from all sources were negative for CD14, CD31, CD34, CD45, CXCR4, SSEA-3, and 
negative or slightly positive for SSEA-4 (only on MSCs) (Paper I). Additional markers on 
DSCs were investigated in Paper II, including CD14, CD86, EpCAM, VCAM-1, and HLA-
G. DSCs have no expression of these markers. Of the markers, VCAM-1 has been shown to 
be inducible on MSCs in mice by activated splenocytes, or IFN-γ with IL-1 or TNFα, but it is 
not constitutively expressed304.  
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Figure 7. Representative plots of the surface phenotype of decidual stromal cells. Filled histograms represent 
stained samples and transparent histograms represent isotype controls. 
Distinct differences were observed when the expression of adhesion molecules was 
determined. DSCs had significantly higher expression of CD49d, CD29, PD-L1, and ICAM-
1 compared to MSCs (Paper I). Interestingly, ICAM-1 has previously been reported to be 
involved in MSC-mediated contact-dependent suppression of immune responses304. The 
expression of CD49d and CD29 may also indicate an ability to home to inflamed tissue, 
although no evidence for this was given in a subsequent paper where DSC distribution in vivo 
was tracked in patients with cGVHD118.  
In contrast, while MSCs from bone marrow are able to differentiate into bone and fat, all 
stromal cells isolated from the different parts of the placenta did not differentiate into bone 
and fat. Whether or not stromal cells from term placentas have differentiation capabilities is 
debated. Work by In’T Anker et al. and many others have shown that stromal cells from 
placenta and decidua have the ability to differentiate274,338,339. Conflicting reports by 
Kanematsu273 et al. and Pilz340 et al. among others showed results in line with ours. It is 
important to note that the isolation techniques used in these papers and in Papers I‒V were 
similar, but they differed in some respects. Kanematsu and In´T Anker both only used the 
trypsin digests for isolation of the stromal cells, and they did not culture membrane pieces in 
addition to the trypsin digests. Pilz used collagenase and cultured pieces of membrane. A 
recent review by Kmiecik et al. discussed the various results regarding differentiation 
potential to (above all) osteoblasts and how the osteogenic potential can be enhanced 
depending on the site of isolation and on selection of stromal cells based on cell-surface 
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marker expression339. Although most MSCs are cultured with passaging, the gradual loss of 
differentiation potential following in vitro expansion of MSCs has not been discussed341,342. 
Many factors may influence the diverse results, including cell origin, isolation and expansion 
of the stromal cells, and the methods used for determination of the characteristics.  
Following the initial isolation of stromal cells from the various placental tissues, a pure 
population of stromal cells is not obtained. For instance, the isolates contain epithelial cells. 
When isolating cells from the fetal membranes, epithelial cells are present both in the trypsin 
digests and on the fetal membranes. When the cells are seeded for the first time, epithelial 
cells adhere to the plastic. However, following the incubation period, the epithelial cells are 
unable to proliferate, yielding a pure stromal cell population after the first harvest (passage 0 
to passage 1). Amniotic epithelium (AE) is one of the placenta-derived cell populations that 
have also been identified as a source of cells that may be used as cellular therapy in 
regenerative medicine343. These cells also have differentiation capability344, and 
immunomodulatory capability. However, expansion of epithelial cells requires a different 
cultivation medium331,345. The DMEMcomp medium that we use is therefore selective for 
stromal cells and not epithelial cells. Due to the fact that AE has differentiation capability; 
there is the possibility that AE could differentiate into stromal cells during the 
expansion346,347. In Paper I, we cultured AE in DMEMcomp. We did not observe 
differentiation into stromal cells, and these cells were not able to expand in the culture 
medium. AE is of fetal origin and is easily isolated from the amnion that is attached to the 
chorionic plate. A pure AE population can therefore be obtained. One thing that is certain 
about AE is that it is of fetal origin. Additional proof for no AE being present in the cultures 
was given in Paper II, where PCR with primers using microsatellite polymorphism in the 
mother and child was used to determine the origin of the cells. We could clearly see that the 
cultured DSCs were of maternal origin. The maternal blood and cord blood (or AE) were 
used to identify the mother and the child, respectively. The conclusion from this analysis was 
that the stromal cells that we cultured did not originate from chorion or amnion, since these 
tissues are of fetal origin. One issue in Paper I when we investigated stromal cells isolated 
from different parts of the placenta was that the origin of the cells was not determined. In our 
hands, DSCs appear to be favored by our isolation and cultivation protocol. This may very 
well have led to contamination of DSCs in the stromal cell isolates from chorion. The 
anatomical difference in the amnion (mechanically separated from the chorionic plate, Figure 
5) increase the probability of these cells originating from the fetus. The stromal cells isolated 
from the amnion also had reduced proliferative ability compared to the other cell isolates. 
Chorionic stromal cells were isolated from the fetal membranes. We therefore concluded that 
these cells are most likely DSCs, like the cells isolated from whole fetal membrane (FMSCs). 
The anatomical separation from maternal tissue in the isolation of PVSCs and UCSCs limits 
the possibility of these cells originating from the mother. PVSCs were isolated from the fetal 
side of the chorionic plate (Figure 5)348. In retrospect, it can be debated whether PVSCs 
should have been referred to as stromal cells from the chorionic plate rather than from the 
placental villi.    
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Before publication of Paper II, the origin of DSCs was unknown. Despite the fact that the 
cells are isolated from fetal tissues, they are of maternal origin. A recent review has 
highlighted the confusion regarding the origin of stromal cells isolated from placental 
tissue282. Among the studies in which cells have been isolated and cultured from placental 
tissue, the characterization of the cells has been poor. Many of the studies published have 
actually shown that the incidence of maternal origin of the stromal cells isolated is high 
(approximately half of the studies investigated), especially in papers where cells were isolated 
from the fetal membranes.  
One of the main findings in Paper II was the in vitro expansion potential of DSCs. In Paper 
II, DSCs from four donors were isolated and expanded. To date, DSCs from a total of seven 
placental donors have been expanded and used (Papers II and V). The total number of cells 
expanded from each donor is presented in Table 1 (last updated June 2015). Others have 
published data where the expansion of stromal cells from different sources has been 
compared273,274. With addition of the results in Paper II and in Table 1, it can be concluded 
that DSCs have a great expansion potential, and a large number of cells can be obtained at 
low passage number. An exponential expansion of DSCs in vitro raises the concern of altered 
properties of the cells. As presented in Paper II, DSCs have a normal karyotype following 
expansion, suggesting that no severe chromosomal alterations have occurred.  
Table 1. Presentation of the total number of decidual stromal cells (DSCs) expanded from seven donors. Passage 
refers to the passage number to which the DSCs have been expanded. Expansion completed shows the present 
expansion status for each donor. For the donors where DSCs are still available, an estimate for the completion of 
expansion to passage 4 was made. This was based on the growth coefficient of each donor, and the number of 
DSCs available in passages lower than 4. 
 
 
4.2 IMMUNE MODULATION IN VITRO 
Evaluation of the immunomodulatory functions of stromal cells by determining their ability 
to inhibit alloantigen-stimulated proliferation in MLRs was the first step in Paper I. This was 
an important characteristic for one of the specific aims of Paper I, which was to compare the 
features of tissue-specific stromal cells in the allogeneic setting. Stromal cells from all 
sources except placental villi were able to suppress proliferation in the MLRs (Paper I). The 
lowest proliferation was observed in the MLRs with added MSCs or DSCs. As reported 
earlier in the literature288, we also determined that all stromal cells alone are capable of 
Placenta(ID( Cells(expanded(
(×109)(
Passage( Expansion(
completed((P4)((%)(
FM1( 1.8( 2B3( 100(
FM3( 3.6( 2B4( 100(
FM7( 2.7( 2B4( 100(
FM8( 5.3( 2B4( 40(
FM11( 1.5( 2B4( 20(
FM13( 1.8( 2B4( 18(
FM14( 1.9( 2B4( 13(
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inducing a small proliferative response when cultivated with PBMCs of allogeneic origin 
(Papers I and III). These data suggest that stromal cells are immunogenic, despite having an 
immune inhibitory function in a highly inflammatory setting such as the MLR. The 
hypothesis regarding MSCs being immune privileged has also been questioned recently349. 
The data presented in Papers I and III―as well as other reports and the suggested role of 
MSCs as functional APCs―indicate that MSCs can induce innate292 and adaptive immune 
responses307. In the clinical setting, DSCs have been shown to induce anti-HLA antibodies in 
immunocompetent individuals, whereas immune suppressed patients do not develop 
antibodies350. Also, there are only limited data on whether stromal cells avoid cytotoxic T cell 
activity. However, one study has shown that allogeneic T cells primed with PBMCs from the 
same donor as the MSCs, lyse MSCs to a lesser extent than PBMCs351. This is based on the 
assumption that PBMCs from the same donor as the MSCs will prime the same T cell 
population. This may exclude activation of T cells by tissue-specific minor histocompatibility 
antigens presented by the MSCs. The conclusion is that MSCs are not immune privileged. 
Still, third-party stromal cells from various tissues are immunosuppressive in the allogeneic 
setting. To explore this further, and the possible differences between stromal cells from 
various compartments of the placenta and MSCs, cytokine concentrations of IFN-γ, IL-10, 
IL-17, and IL-6 in supernatants from the MLR cultures was determined (Paper I). Addition 
of stromal cells from either source induced a small production of IL-17, IL-10, and IL-6 when 
added to PBMCs. In the MLR setting, the presence of DSCs or UCSCs reduced the 
concentration of IFN-γ in the MLRs. In the same setting, IL-10 was increased. In contrast, 
while UCSCs increased the concentration of IL-17 in the allogeneic setting, DSCs reduced 
the IL-17 concentration. This is also in line with the IL-6 results, where DSCs had the lowest 
background production of IL-6 and a low median production of IL-6 in the MLR setting 
compared to other stromal cells. As mentioned, IL-6 is a key cytokine for induction of Th17 
cells71. IL-6 was increased under all conditions where stromal cells were added. MSCs did 
not significantly alter any cytokine concentrations other than that of IL-6, when added to the 
MLRs. Other reports have suggested that MSCs can either induce352 or suppress IL-17 and 
Th17 production and differentiation353,354. In a setting with purified T cells and anti-
CD3/CD28 stimulation, DSCs did not increase the concentration of IL-10 after 3 days (Paper 
I). This may be interpreted in two ways: either the induction of Tregs and their subsequent 
IL-10 production takes longer than 3 days (Tregs are induced by DSCs in MLRs, Paper III), 
or one of the cell types removed in this particular assay (e.g monocytes355) is the main 
producer of IL-10 in the MLR setting. Either way, IL-10 does not appear to be crucial for 
DSC-mediated suppression. Blocking of IL-10 with an anti-IL10 antibody does not impair 
the antiproliferative ability of DSCs (Paper III). IL-10 is not necessary for a successful 
pregnancy265, but the levels of IL-10 are increased during pregnancy and reduced IL-10 
concentrations are also associated with spontaneous abortion356. Provocatively, this might 
suggest that IL-10 is just a factor that results from the generation of Tregs and M(IL-10), 
which are of greater importance for the maintenance of feto-maternal tolerance. A more 
rational explanation would be that IL-10 is important in pregnancy, but that cells other than 
DSCs maintain IL-10 production.  
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One of the prerequisites for finding a new cell source for the clinical setting was the ability to 
suppress the inflammatory profile in the MLR. PVSCs did not suppress the proliferation in 
MLR, and although the UCSC setting showed a high IL-10 concentration, IL-17 was 
significantly increased and the concentration of IL-6 was high compared to DSCs. DSCs had 
a consistent antiproliferative ability, reduced IFN-γ and IL-17, increased IL-10, and a high 
expression of integrins that might be of importance in the clinical setting. Based on this, 
further studies in Paper I and Paper III were therefore focused on DSCs and MSCs. In 
Paper IV, we concentrated entirely on DSCs.  
Many of the immune-modulatory effects of MSCs are dependent on initial priming of these 
cells―with, for example, IFN-γ, IL-1α/β, and/or TNFα 291. Following pretreatment with IFN-
γ, MSCs upregulate the expression of HLA class II306, which may enable them to prime 
CD4+ T cells284. In Paper I, we also found that the expression of PD-L1 and ICAM-1 was 
increased by IFN-γ (Figure 8). Interestingly, DSCs did not express HLA class II upon IFN-γ 
stimulation. In addition, the intensity of expression of PD-L1, CD49d (α4 integrin), and 
ICAM-1 was higher on DSCs than on MSCs. Although not confirmed in Paper I, the low 
expression of HLA class II and CD86 may reduce the possibility of DSC-mediated priming 
of CD4+ T cells. This finding contradicts the study by Olivares et al., which found that DSCs 
treated with progesterone in vitro and isolated from the first trimester could express both 
HLA class II and CD86357. Another study by Nagamatsu et al. suggested that term DSCs 
(although isolated differently from those in Papers I‒V) may upgregulate expression of 
HLA-DR when treated with IFN-γ, but not when treated with TNF-α358. Another finding that 
characteristically distinguishes DSCs from MSCs294 is constitutive expression of IDO,  as 
presented in Paper III. According to immunofluorescence staining, as well as FC, DSCs 
have a constant expression of IDO and this expression is not significantly increased by IFN-γ. 
However, subsequent analysis of RNA expression showed low transcriptional levels of IDO 
RNA in unstimulated DSCs, while levels were increased when the DSCs were stimulated 
with IFN-γ (Solders et al., unpublished). The same analysis for HLA class II molecules has 
not been performed with DSCs yet. These data may indicate that IFN-γ may have a slightly 
different role in immune suppression in DSCs than in MSCs. Priming of MSCs with IFN-γ 
increases their antiproliferative effect, while the same pretreatment of DSCs actually gives 
reversed results (Paper III). Despite this, blocking of much of the IFN-γ present in the MLRs 
leads to a reduced antiproliferative effect being exerted by the DSCs (Figure 9). This may 
lead to the conclusion that DSCs need a small amount of IFN-γ to retain certain 
functions―such as production of IDO and expression of PD-L1, HLA class I molecules, and 
integrins. On the other hand, high concentrations of IFN-γ may increase functions on the 
DSCs that support the alloproliferation, and this was not investigated in Papers I‒V. We did 
not observe an increased expression of HLA class II molecules, which should to some extent 
prevent DSCs from acting as APCs for CD4+ cells. But this does not exclude the possibility 
that DSCs cannot provide co-stimulatory signals to CD4+ T cells. The increased expression 
of ICAM-1 should enhance the interaction with T cells and allow interaction through, for 
example, PD-L1 or HLA class I, the expression of which is also elevated in the same setting.  
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Figure 8. Representative plots of phenotype of decidual stromal cells (DSCs) and bone marrow-derived 
mesenchymal stromal cells  (MSCs). The transparent histograms are isotype controls, light gray histograms are 
untreated cells, and dark gray histograms are plots where the cells were stimulated with 100 U of interferon-γ for 
48 h prior to analysis.  
Further studies regarding these findings may explain how IFN-γ affects DSCs, which would 
be of great interest. For instance, the expression levels and responsiveness of the IFN-γ 
receptor (CD119) in DSCs are unknown, as is the level of activation of the major signaling 
pathways following JAK1/2 phosphorylation on the IFN-γ receptor. The findings in Papers I 
and III should be confirmed with alternative methods, but the conflicting results in the same 
setting with different cell types still indicate that the responsiveness to IFN-γ may differ 
between DSCs and MSCs. Other suggested mechanisms that may influence the differences 
seen with IFN-γ priming could be gene silencing of, for example, HLA class II, which has 
been reported to inhibit production of chemokines in the decidua246. Additionally, there are 
other factors (apart from IFN-γ) that can increase the expression of IDO, such as PGE2359,360. 
PGE2 is another factor that may be of importance for DSC-mediated suppression (Paper III, 
Figure 9). As PGE2 may induce expression of IDO, the results in Paper III do not explain 
whether the immunosuppressive effect seen when blocking PGE2 is a direct consequence of 
the immune-modulatory effect of PGE2 or an indirect mechanism that is the result of 
impaired IDO production. The functions of PGE2 are diverse, and they can be regarded as 
being both proinflammatory and anti-inflammatory, as PGE2 is a main activator of early 
inflammation (e.g. attraction of innate immune cells to sites of inflammation, vasodilation), 
while affecting some adaptive immune cells to promote an anti-inflammatory shift. In 
adaptive immunity, PGE2 has been shown to inhibit IL-2 production361 and reduce the amount 
of JAK3 in T cells362, indicating a reduced responsiveness to IL-2 in T cells. In contrast, 
studies have shown that PGE2 may also induce the IL-2-dependent Treg subset363,364, Th17 
cells365, and promote a shift towards Th2 cells by inhibiting the cytokine that promotes Th1 
cells―IL-12366. Based on the results in Papers III and IV, PGE2 may be involved in the 
production of IL-10 and generation of Tregs, but the results in Paper IV contradict the role of 
PGE2 and its inhibitory effect on IL-2 production in this setting. However, whether or not 
PGE2 might affect STAT5 phosphorylation (pSTAT5) through reduced JAK3 levels was not 
determined in Paper IV. Interestingly, PGE2 is a factor that plays a pivotal role during 
implantation and promotes tolerance during the first trimester. 
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In response to IL-1α, stromal cells in the uterus have been reported to produce PGE2 in 
experimental models367. IL-1 was present at high levels in our in vitro experiments (data not 
shown), which supports the idea of PGE2 being a suppressive mediator induced by DSCs in 
the allogeneic setting in vitro.  
One of the factors that appears to be of major importance for DSC-mediated suppression in 
our setting is IDO. Inhibition of IDO activity reduces the ability of DSCs to suppress the 
MLR (Paper III). In addition, inhibition of IDO reduces the frequency of Tregs in the 
cultures (Paper III). These results are in line with the work of many others295,368-370. 
Interestingly, many of the findings in Paper III may be derived from the presence of IDO. 
We are not aware of any link between IDO and PD-L1. However, even though IDO appears 
to be important for the immunosuppression in vitro, the data in Paper III also show that IDO 
cannot be the only mediator of suppression. The proliferation of the MLRs is reduced when 
stromal cells are added to the culture. However, if the stromal cells are added in a transwell, 
the antiproliferative effect in the MLR is reduced, as is the frequency of Tregs. This supports 
the idea that the DSC-mediated suppression in vitro is also at least partly dependent on 
contact with the cells in the MLR. The frequency of Tregs is increased compared to control 
MLRs when the DSCs are also placed in the transwell, which could in part be a result of the 
soluble products originating from IDO activity―or it could be due to the DSC’s constitutive 
production of TGF-β. MSCs are able to suppress the MLR in a transwell, which is also in line 
with their ability to upregulate secretory immunomodulatory functions due to the presence of 
IFN-γ, IL-1α/β, and/or TNFα in the cultures. The results in Papers I and III indicate that 
DSCs are affected differently by IFN-γ, which could hypothetically reduce the ability of 
DSCs to suppress the MLRs from a distance. As presented in Papers I and II, DSCs express 
PD-L1 and PD-L2. When we blocked PD-L1 in the cultures, the proliferation was increased 
(Figure 9). The interaction between PD-L1/PD-L2 and PD-1 requires cell-to-cell contact. 
One of the drawbacks of this assay is that PD-L1 is blocked on the DSCs and on any other 
cells that may express this in the culture (e.g. macrophages). Even so, the addition of an anti-
PD-L1 antibody increased the proliferation in the MLRs, indicating that PD-L1/PD-1 
interactions are involved in immune modulation by DSCs. Engagement of PD-1 by PD-L1 
inhibits signaling through the TCR371,372. The inhibitory signaling by PD-1 can, however, be 
overcome by a strong co-stimulation of CD28 and/or IL-2. In Paper IV, we found that the 
MLR and DSC co-cultures resulted in a high concentration of IL-2 in the supernatant. One 
could therefore speculate whether the high concentrations of IL-2 in the cultures would mask 
a higher significance of the PD-L1/PD-1 axis in this setting. Apart from interaction between 
PD-L1 and PD-1, PD-L1 has been shown to bind to CD80, making it an additional 
competitive binding molecule besides CD28 and CTLA-4373. In Paper III, blocking of PD-
L2 was also done. This, however, had no effect on the proliferation of the MLR, and there 
was no additive effect of combined blocking of PD-L2 and PD-L1.  
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Moreover, we did not observe that some of the other factors that we blocked had an influence 
on the proliferation of the MLRs. Blocking of the activity of IL-17, TGF-β, or HLA-G did 
not affect the antiproliferative ability of the DSCs.  
The increase in Tregs in the MLRs with DSCs is interesting (Figure 9). It has also been 
shown that Tregs are enriched in decidual tissue90. It can unfortunately only be speculated 
what subtype of Tregs is present in the cultures, and whether these cells have a central or an 
effector phenotype. The increase seen at 6 days may depend of a variety of factors: an 
expansion of inducible or naturally occurring Tregs (nTregs), a differentiation of inducible 
Tregs (iTregs), or increased survival ability of the Tregs in the culture compared to other cell 
types in this setting. The work in Paper III shows that the frequency of Tregs is to some 
extent increased when the DSCs are placed in a transwell. As DSCs are a source of TGF-β, 
this may induce FOXP3 expression in CD4+CD25+FOXP3− cells98. One interesting 
hypothesis that might be investigated is also whether the contact-dependent and non-contact-
dependent DSC interactions promote different types of Tregs. Functional studies and further 
in-depth analysis of the Tregs may explain the importance of these cells in this setting. Such 
analysis might include expression of CCR7 and CD62L92,93, to determine whether the cells 
are of an effector or central phenotype. Cytokine secretion and suppressive capacity can be 
used to explore the functionality. Helios has previously been suggested as a marker that can 
be used to identify Tregs that originate from the thymus (naturally occurring Tregs)374. This 
has, however, been questioned in a study where this Treg subset was shown to have an 
inconsistent expression of Helios, while still having functional similarities375. A more recent 
study found that CD15s were expressed on Tregs with a high suppressive capacity376. 
Combined analysis of these factors may explain the importance of Tregs in this setting. A 
guess in this case would be that DSCs promote differentiation of inducible Tregs, as the 
population that contributes to the increased frequency has lower intensity of expression of 
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Figure 9. Top panel: Addition of blocking agents for 
indoleamine-2,3-dioxygenase (IDO), prostaglandin E2 
(PGE2), programmed death ligand-1 (PD-L1) or 
interferon (IFN)-γ reduces the antiproliferative effect of 
decidual stromal cells (DSCs) in mixed lymphocyte 
reactions (MLRs). Bottom panel: The frequency of 
regulatory T cells (Tregs) when IDO is blocked (left) and 
the frequency of Tregs when the DSCs are placed in a 
transwell. Abbreviations: 1-MT, 1-methyl-DL-
tryptophan; Trans, transwell.
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FOXP3 than the control MLR setting. This may indicate unstable expression of FOXP3 and 
the inducible state of FOXP3 gene expression seen in T cells that are dependent on TGF-β to 
maintain a FOXP3+ phenotype377. The expression of FOXP3 in nTregs is regarded as being 
fairly stable378,379. However, stability of the FOXP3 expression in iTregs and nTregs is still 
debated. Interestingly, differences in the frequencies of Tregs could not be seen in Paper V 
between patients who had a lower grade of GVHD and patients who deteriorated after 
systemic administration of DSCs.  
Furthermore, the plots in Paper III that show the frequency of Tregs in the MLRs was also 
one of the underlying reasons for the investigation of IL-2 in this setting, which was part of 
Paper IV. Here, we observed for the first time that DSCs in contact with the MLR had 
drastically increased expression of CD25 (IL-2Rα).  This is an indication of IL-2 production. 
Determination of the concentration of IL-2 in the supernatant of these cultures showed a high 
concentration of IL-2 in the MLR + DSC condition. If the DSCs were put in a transwell, the 
IL-2 concentration in the supernatant was low, indicating that the DSCs may contribute to 
this. The DSCs themselves are unable to produce IL-2. The concentration of IL-2 peaked at 
day 3‒4 of incubation. Interestingly, others have presented data of high IL-2 levels under 
conditions with stromal cells380-383, but the phenomenon has not been addressed in detail. 
However, the induction of IL-2 in the allogeneic setting is not peculiar, and it fits into the 
context of the MLR as a highly T cell proliferative milieu and supports the findings of MSCs 
inducing Tregs95,384,385. This leads to the question: why are the levels of IL-2 high in these 
cultures? IL-2 is regarded as an autocrine/paracrine cytokine that is produced and rapidly 
consumed, leading to T cell expansion and proliferation119,120.  
In Paper III, the expression of CD25 was investigated, but little was known regarding the 
expression of the other IL-2R subunits, the common γ-chain (γc, CD132) and the β-chain 
(CD122) on T cells in this setting. In Paper IV, the expression of CD25 was mapped in a 
large number of experiments. In our hands, the frequency of CD25 was not changed when 
DSCs were added to the MLR. The intensity of expression of CD25 was, however, 
consistently elevated to a high degree. In vivo data on cells isolated from the decidua 
parietalis and peripheral blood have shown that CD25 expression is elevated during 
pregnancy386, indicating that our findings may to some degree be associated with the in vivo 
situation during pregnancy. CD132 was constitutively highly expressed on T cells, but its 
frequency and intensity of expression was reduced in the MLR + DSC setting. CD122 has 
low constitutive expression; it was upregulated in the MLR, and the expression was 
comparable to the unstimulated situation when DSCs were added to the MLR. The intensity 
of expression in the MLR+DSC setting was reduced compared to the MLR. Finally, when 
investigating the combined frequency of expression of the high-affinity IL-2R, we observed 
that the expression was low in the MLR + DSC setting on day 6 of incubation (Figure 10). 
These results were associated with reduced pSTAT5 expression in both CD4+ (trend) and 
CD8+ cells (Figure 10), but not in Tregs, although the intensity of pSTAT5 was also reduced 
in the Tregs (Paper IV). Tregs are regarded to be more dependent on IL-2 for expansion94,95. 
While not all CD4+ cells or CD8+ cells were able to phosphorylate STAT5 upon IL-2 
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stimulation, all Tregs were pSTAT5+ following IL-2 stimulation at the end of the incubation 
period.  
There are some factors that may influence this setting. Soluble IL-2Rα expression is 
increased in response to IL-2. Increased levels of this factor are also associated with 
GVHD387,388.We did not detect any difference in soluble IL-2R concentration when stromal 
cells were added to alloantigen-stimulated PBMCs in vitro. Another factor that has been 
identified and must be taken into account in this setting is the possibility of alternative 
splicing of IL-2 RNA, where IL-2 derived from spliced versions may block the IL-2R389,390. 
We could not, however, identify any differences between our in vitro conditions regarding 
alternative splicing. Taken together, these results suggest that soluble IL-2 and alternative 
splicing of IL-2 have little impact in our setting. Additionally, conditioned medium from 
MLR + DSC cultures was also capable of stimulating phosphorylation of STAT5 in T cells to 
the same extent as 10 ng/ml rIL-2.  
Previous studies in mice by another group have shown that addition of IL-2 to a culture with 
allo-stimulated T cells and MSCs reverse the T cell anergy induced by the MSCs, and restore 
proliferation in this setting391. In Paper IV, IL-2 was added at the beginning of the 
experiment and the response was measured on day 3. On that day, expression of IL-2R was 
still high (Erkers et al., unpublished observations), and addition of IL-2 would stimulate 
further expansion of the PBMCs. Addition of IL-2 at this stage may overcome the negative 
signaling of, for instance, PD-L1―as discussed previously. However, the data in Paper IV 
suggest that if the experiment is given further incubation, the T cells will become less 
responsive to IL-2. This will ultimately leave the cells unable to be saved by addition of 
exogenous IL-2.  
Due to the kinetics of IL-2R expression, experiments in which DSCs were exchanged for 
recombinant IL-2 showed that the reduction in CD122 expression could be seen with addition 
of an equal concentration of IL-2 to that detected in the supernatants on day 3. The high IL-2 
concentration may in part be responsible for the depletion of CD122 expression. In Paper IV, 
we suggested that the reduction in pSTAT expression might be due to the depletion of IL-2R. 
Combining this with the results of Paper III, PGE2 could also be a factor that influences the 
expression of pSTAT5362. Other cytokine receptors that express CD132 include IL-4392, IL-
7393, IL-9394, IL-15395, and IL-21396; they may also influence the output in these in vitro 
assays. In comparison, the levels of these cytokines are very low in our setting compared to 
that of IL-2 (Erkers et al., unpublished observation). We did not do any further investigation 
of IL-15 in this setting, despite the fact that it shares CD122 and CD132 with IL-2, and the 
signaling pathway is very similar397. One way of finding out whether reduced pSTAT5 
expression is due to depletion of the IL-2R is to add 125indium-labeled rIL-2 to the cultures 
(Figure 10). Our hypothesis is that [125I]rIL-2 is taken up by the cells with IL-2R, and that 
this may vary depending on the expression of IL-2R.   
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Although there was a high amount of IL-2 (low IL-2 levels being an indication of 
exhaustion398), the data presented in Paper IV regarding IL-2R expression may indicate that 
the PBMCs in the cultures had a higher rate of exhaustion. Previous studies have also 
indicated that high concentrations of IL-2 have a pro-apoptotic effect124. We therefore 
determined the expression of PD-1 and CD95, which may be associated with exhaustion in 
chronic infection399,400. Although IL-2 expression is increased and IL-2R expression is 
reduced in the MLR + DSC setting, no differences in PD-1 or CD95 expression could be seen 
compared to the control MLR setting. Interestingly, addition of a large dose of IL-2 to the 
MLRs increased the frequency of CD95+ cells, while the PBMCs incubated with DSCs in the 
MLR did not upregulate expression of CD95. This is in line with other data indicating that 
DSCs prevent apoptosis in lymphocytes401, and that IL-2 in high concentrations induces 
CD95402 and apoptosis 124.  
The underlying reason for increased IL-2 concentration in the presence of DSCs was not 
determined in Paper IV. Experiments where intracellular staining was performed showed 
that the production of IL-2 occurs in T cells (Paper IV). The number of experiments was, 
however, low, and other cell subsets were not investigated. Further experiments to reveal 
factors of importance for the induction of IL-2 in this setting are important. Despite the low 
expression of HLA class II molecules on DSCs, these cells are a source of allo-recognition 
that, while they still work regularly in a suppressive fashion, are able to provide stimulation 
(TCR) that may trigger IL-2 production. While the data in Papers I‒III may indicate that 
DSCs have a reduced ability to provide co-stimulation (no expression of CD80 and CD86, 
Figure 7), the allogeneic setting probably play a large role in providing co-stimulatory 
signals, as PBMCs cultivated with allogeneic DSCs do not appear to alter IL-2 production 
significantly. This is an important point, as MLRs in particular are an in vitro model for the 
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Figure 10. Expression of the high-affinity interleukin (IL)-2 receptor 
(CD25+CD122+CD132+) on CD8+ T cells on day six of incubation (left). The cell 
cultures consisted of peripheral blood mononuclear cells (PBMCs) or mixed 
lymphocyte reactions (MLRs) with decidual stromal cells (DSCs) added. The uptake 
of external radioactive IL-2 was reduced when DSCs were added to the MLR cultures 
(middle). The frequency of CD8+ T cells that were able to phosphorylate STAT5 was 
also reduced in this setting (top right). Also, those cells that were pSTAT5+ had a 
reduced intensity of expression of pSTAT5 (bottom right). 
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HSCT setting rather than for gestation. The data support the idea that DSCs promote IL-2 
production, which subsequently leads to depletion of the full IL-2R complex―which may in 
turn explain the reduced pSTAT5 and IL-2 uptake in alloantigen-activated T cells in vitro.  
In the HSCT setting, the use of immunosuppressive drugs is crucial to handling the 
alloreaction after transplant. One type of immunosuppressant―e.g. CyA and SRL―to some 
extent targets the downstream signaling of IL-2 (Figure 3). We therefore found it of interest 
to investigate the combined effect of DSCs and CyA or SRL in the allogeneic setting in vitro. 
From previous publications, it is known that IL-2 may reverse the immunosuppressive effects 
of CyA403. A high dose of CyA can then be used to overcome this. In contrast, several studies 
have reported various synergistic tolerogenic effects of MSCs and immunosuppressive 
drugs404-407. We therefore combined DSCs and CyA or SRL in MLRs, and measured 
proliferation between days 5 and 6 of incubation. Addition of DSCs or CyA/SRL 
independently suppressed proliferation of the MLRs. Combination of DSCs and CyA 
suppressed the culture, but the proliferation was not synergistically reduced further. In 
contrast, combination of SRL and DSCs did not result in reduced proliferation compared to 
control MLRs. The proliferation in the DSC + SRL situation was also significantly higher 
than in the situation with only SRL added to the MLR. This result is in line with the results of 
another study, by Buron et al., where a combination of MSCs with CyA or SRL increased 
proliferation in the allogeneic setting compared to adding MSCs alone408. The mixed results 
regarding this important interaction (in the context of cellular therapy) deserve further 
investigation. Determination of the mechanism of the interplay between DSCs and 
immunosuppressive drugs may be an important step to improving the therapy and safety. 
These results also indicate that the IL-2/IL-2R phenomena observed in Paper IV may be 
important for the reduction of proliferation by DSCs in vitro.  
 
4.3 IMMUNOTHERAPY WITH DECIDUAL STROMAL CELLS 
Based on the data presented in Papers I and II and the literature on MSC-based therapy, 
DSCs were introduced as a second-line therapy for severe GVHD (as decided by the principal 
investigators and the physician responsible). In Paper II, nine patients with severe GVHD 
were treated with DSCs. The dose of DSCs ranged between 0.9 and 2.8 × 106 cells/kg. All 
patients but one received RIC. All of them had gastrointestinal GVHD. The DSCs were given 
between 23 and 219 days after transplant.  Five of the patients received more than one DSC 
infusion, and a total of 15 infusions were given. The three patients who were alive at 6 
months after transplantation were still alive three years after HSCT (Solders et al., 
unpublished data). The patient material in Paper II was small, and no certain conclusions 
could be drawn regarding the safety or the efficacy of the DSC treatments. Several severe 
adverse events (SAE) occurred after the treatment to the end of the follow-up. Since many of 
these could be transplant-related complications, it is difficult to link the SAEs observed to the 
DSC treatment in Paper II, as there were too few patients and no consistent SAE occurred in 
most of them. Stromal cell treatment has not been associated with infusion toxicity, but later-
occurring events have been reported, including reduced immune reconstitution323 and an 
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increased risk of development of post-transplant lymphoproliferative disease (PTLD)324 or 
death due to pneumonia409. A long-term follow-up including more patients should reveal the 
risk factors associated with DSC therapy. 
The survival rate until 3 years after transplantation was comparable to those in other recent 
GVHD-related reports where MSCs were used309,310. In these studies, there was no difference 
in survival between the groups that received the treatment and matched historical controls. 
Other recent studies where conventional non-cell therapy approaches have been used to treat 
GVHD have shown limited results, and includes the addition of mycophenolate mofetil to 
standard steroid treatment410 or the use of an IL-1R antagonist411. The conclusion is that at the 
moment, there are very few other reliable treatments besides corticosteroids for patients with 
severe GVHD. 
Since Paper II was a pilot study, few parameters regarding the clinical protocol for DSC 
treatment had been subject to optimization. There are several factors that might be altered to 
improve the protocol. The dose was based on previously published data on MSCs. 
Interestingly, there have been no studies in man―except for one where the dosages of MSCs 
were investigated412. The literature has reports of MSC doses ranging between 0.4 and 9 ×106 
cells/kg311. Another parameter that may play a role is the number of interventions. Should 
treatment be one time only, or should it be given repeatedly? One study suggested that 
several infusions may be beneficial413. In Paper II, multiple infusions in five patients resulted 
in a reduction in GVHD in two out of the five after the treatment(s) following the initial 
treatment. The time point for the intervention may also influence the outcome of the 
treatment. For instance, should treatment be given at an earlier stage of GVHD progression in 
an attempt to prevent further progression? Is there a threshold in GVHD pathophysiology 
where intervention is meaningless? Moreover, handling of DSCs before treatment may also 
have importance for the efficacy of treatment. Replacement of the washing solution after 
thawing―from AB-plasma to serum albumin―considerably increased the viability of the 
DSCs administered to the patients (Solders et al., unpublished) (these patients are included in 
Paper IV and V). Further studies to establish a more optimized protocol for DSC dose, time 
of intervention, and cell handling are important for further clinical use of DSCs and other 
cell-based interventions for GVHD and other diseases.  
Ex vivo analysis in Papers IV and V was based on the data obtained from patient samples 
that were obtained before and several time points after infusion with DSCs. Parts of these 
samples were subsequently analyzed by FC and Luminex.  
To some extent, it was possible to analyze (ex vivo) the altered IL-2/IL-2R effects shown in 
vitro in Paper IV. The lack of analysis of CD132, CD122, and pSTAT5 was due to the fact 
that the work described in Papers IV and V was performed simultaneously. It was possible to 
analyze the peripheral blood concentration of IL-2, the expression of CD25, and the 
proportion of Tregs. Based on the different results when combining DSCs with SRL or CyA 
in vitro, the patients were divided based on which one of the two drugs they received as 
GVHD prophylaxis and as treatment for GVHD. This treatment was continued during the 
GVHD therapy. Also, all patients were combined to find changes in these parameters in the 
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whole patient material. In vitro, addition of DSCs to an MLR was associated with a 
consistent increase in the intensity of expression of CD25 in CD25+CD4+ T cells following 6 
days of incubation. This could not be detected at any time point following infusion in either 
of the groups, nor in the combined patient material (Paper IV). Moreover, no significant 
change in the frequency of CD25+ cells, the proportion of Tregs, or the concentration of IL-2 
was detected when analyzed in the same manner. These data are difficult to analyze and to 
put in context of the in vitro findings unless experiments in the DSC+SRL/CyA setting are 
explored in more detail in vitro. For instance, the expression of IL-2R subunits and IL-2 
concentration should be determined in vitro, correlated with the proliferation response in the 
MLRs, and compared to the clinical data. Additionally, it is important to note that the 
expression of CD25 and production of IL-2 in the clinical setting may be heavily influenced 
by the immunosuppressive drugs and immune reconstitution following HSCT. The patients 
also received tacrolimus (which is comparable to CyA). This might conceal the separate 
effects of CyA or SRL alone. One randomized study involved surveillance of the levels of IL-
2 and Tregs following treatment with MSCs for GVHD. In that material, the concentration of 
IL-2 and the frequency of Tregs were higher in the treated cohort than in untreated controls at 
one month381. Another study evaluated IL-2 concentrations in MSC-treated GVHD patients 
but used the data to correlate the concentrations to clinical outcome222. No findings regarding 
how IL-2 concentrations following treatment are correlated to outcome were reported.  
The clinical data in Paper IV show no significant alteration in the SRL condition compared 
to the patients who did not receive SRL, indicating that no interference between the SRL and 
DSC therapy related to CD25 expression and IL-2 concentration occurs. For the clinical 
evaluation of the material presented in Paper IV, analysis where the patient material is 
divided based on type of first-line GVHD prophylaxis/treatment is nonetheless encouraged in 
future studies with a larger patient material.  
The parameters investigated ex vivo in Paper IV were also included along with others in 
Paper V. In that paper, we followed immunological parameters following treatment with 
DSCs for severe GVHD. Three patients received a new DSC treatment later than one month 
after their first DSC treatment, whereas the new DSC treatment was regarded as a new 
intervention, making the maximum number of interventions investigated to be 25. A total of 
27 soluble factors and over 50 cell subset parameters were investigated in these 25 
interventions. The time points included in the analysis were as follows: before the start of 
DSC intervention, 3 hours after it, and one week, two weeks, and four weeks after the start of 
intervention. All the samples available from each patient were included. A clinical evaluation 
was done and the patients were divided in two groups (responders (n = 17) and non-
responders (n = 8)), depending on GVHD status subsequent to the start date of DSC 
intervention. The data were analyzed to first investigate if there was a difference between the 
responders and the non-responders at the start of DSC infusion, or at any time point after that. 
We also wanted to investigate if any differences could be detected over time in each group or 
in the whole patient material. OPLS-DA with subsequent univariate analysis (Mann-
Whitney) was used to identify factors of importance in the two groups, and Friedman’s test 
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was used to discriminate differences between all time points of measurement in each group 
and in the whole material. In Paper V, the Luminex data and the FC data were analyzed 
separately.  
Interestingly, there were no indications that the in vitro and the ex vivo findings were 
correlated in Papers I, III‒V regarding changes in proportions of specific T cell subsets or 
the concentration of cytokines (e.g. Tregs, CD25 MFIhigh CD4+ T cells, IL-10, IL-17, and 
IFN-γ) over time following introduction of DSCs in the allogeneic setting. Several other 
factors were, however, identified in Paper V that might give an indication of the changes in 
immunological status of the patients. 
Three soluble factors were found to differentiate between the two groups before the start of 
the intervention: IL-6, IL-8, and IP-10 (Figure 11). The non-responders had significantly 
higher concentrations of all these factors before treatment. This was despite the fact that there 
was no difference in clinical parameters between the groups. Other factors associated with 
GVHD, such as IFN-γ, IL-1, and TNF-α, showed no significant differences between the 
groups. Interestingly, several studies have found that IL-6, IL-8, and IP-10 (although not 
analyzed together) can be elevated in GVHD. IL-6 concentrations are increased in the early 
stages of GVHD414 and have been shown to be of importance for GVHD in experimental 
models208. In comparison, the concentration of IL-6 was increased in the presence of DSCs in 
vitro, although the DSCs did not appear to produce IL-6 constitutively to the same extent as 
MSCs (Paper I). This can be compared to stromal cells from placental villi, umbilical cord, 
and bone marrow that do produce IL-6 to some extent (Paper I). However, a significant 
increase in IL-6 could not be detected in either group over time, but the non-responders had a 
higher concentration of IL-6 than the responders four weeks after the start of DSC 
intervention. This is also in line with data indicating that IL-6 mediates GVHD. If the patients 
do not improve regarding their GVHD, they are more likely to have a higher concentration of 
soluble factors associated with GVHD. Of the factors mentioned above, IL-6 was the only 
cytokine that differed significantly between the groups at four weeks. Although IL-6 
concentration was elevated in the non-responders, this group did not have an elevated 
proportion of Th17 cells, which may be induced by IL-6 and TGF-β. Clinical studies have 
suggested that an antibody to IL-6 may be used successfully to reduce the incidence of severe 
GVHD415.  
Moreover, IP-10 was highly elevated in the non-responders compared to the responders. This 
difference decreased over time, to finally become statistically insignificant between the 
groups at 4 weeks. Work of others has shown that IP-10 expression is increased in patients 
with skin GVHD210. In that study, IP-10 was produced by basal keratinocytes at the sites of 
skin GVHD. The levels of IP-10 were higher in our non-responder group than in the patients 
with skin GVHD in that report. The levels of IP-10 in GVHD patients in the paper by Piper et 
al. are comparable to the concentrations detected in the responders in Paper V. This would 
facilitate migration of cells that express CXCR3. As stated earlier, this chemokine receptor is 
expressed on Th1 cells. In Paper V, the median frequency of Th1 cells was lower in 
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peripheral blood of the non-responders than in that of the responders (but not significantly 
so). One of the weaknesses in Paper V was the lack of characterization of cell populations 
isolated from tissue sites of GVHD. Effector cells will migrate to tissues, and the data on 
these populations in peripheral blood should be interpreted with caution. Although not 
mentioned in patient characteristics in Paper V, subsequent analysis regarding the occurrence 
of skin GVHD, 6 of the cases in the responder group had skin GVHD, and 6 of the non-
responder cases had skin GVHD (p = 0.1, non-significant). These data suggest that the trend 
of a higher occurrence of skin GVHD in the non-responders may have influenced the 
disparity of IP-10 concentrations between the groups. Additional analysis of other molecules 
associated with skin GVHD220 may provide further information regarding disparity of skin 
GVHD between the groups. A separate analysis of the data in Paper V with the patients with 
skin GVHD excluded has not been performed, but is encouraged in future work.  
The levels of IL-8―together with those of sIL-2Rα, TNF receptor 1, and hepatocyte growth 
factor―have been suggested to be able predict survival in patients with GVHD416. The main 
function of IL-8 is to attract neutrophils to sites of early acute inflammation. The elevated 
levels of IL-8 may be explained by the tissue damage following transplant, and the levels of 
IL-8 are high in all patient groups after transplant, irrespective of complications after 
HSCT417.  
Decidual stromal cells have been suggested to exert gene silencing to reduce the production 
of chemokines, and by this reduce the migration of immune cells to the feto-maternal 
interface246. Addition of a blocking antibody to one of these chemokines (CCL5) appeared to 
reduce the incidence of severe GVHD in a phase-I study418. In Paper V, increased levels of 
CCL5 were detected in the responders four weeks after DSC intervention. Both innate and 
adaptive immune cells respond to CCL5 and may migrate towards sites of inflammation. 
With the lack of investigation of CCL5 and factors related to this in Papers I‒IV, it is 
difficult to draw any conclusion regarding the impact of this finding other than that an 
elevated level of CCL5 may be linked to the state of inflammation at 4 weeks. This finding is 
therefore somewhat contradictory to the increased levels of IL-6, IL-8, and IP-10 in the non-
responders, which suggest that lower levels of cytokines are linked to GVHD in the 
responders.   
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Figure 11. Graphs to the left show the concentration of interferon-γ-induced protein 10 (IP-10), interleukin (IL)-
6, and IL-8 in peripheral blood of patients with severe GVHD who received decidual stromal cells (DSCs). The 
patients were divided into responders (R) and non-responders (NR) depending on improvement in GVHD status. 
Time points indicate the time from the start of DSC intervention. The graphs on the right present the expression 
of naïve, human leukocyte antigen DR (HLA-DR), and chemokine (C-C motif) receptor 9 (CCR9) on CD4+ T 
cells in peripheral blood in the same setting. Stars in the middle above a line represent a significant difference in 
a patient group over the two time points indicated. Stars directly above the 75th percentile show a significant 
difference between the two groups. *p = 0.01‒0.05, **p = 0.001‒0.01, ***p < 0.001. 
In addition to systemic cytokine levels, we also determined the proportions of certain immune 
cell subsets and markers thought to be of importance in the GVHD setting or in 
inflammation. HLA-DR is upregulated upon T cell activation. Yet, elevated levels of HLA-
DR on T cells have not been reported in GVHD419,420. In Paper V, a decline in HLA-DR-
expressing CD4+ cells in the responder group was observed. In the CD8+ compartment, the 
median level of expression of HLA-DR was higher in the non-responders than in the 
responders, but the difference was not significant. In contrast, the proportion of naïve CD4+ 
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cells in the non-responders was high. Interestingly, while most of the CD4+ T cells in the 
responders were of an effector phenotype, the frequency of cells with a distinct Th1, Th2, 
Th17, or Treg phenotype was not significantly different compared to the non-responders. 
Although not significantly different before DSC treatment, the increased disparity of naïve 
cells between the groups is intriguing. One recent report by Gauthier et al. suggested that low 
levels of IL-7 and DCs during GVHD limited the possibility of homeostatic expansion of 
naïve CD4+ cells in an experimental model421. No differences in IL-7 concentration between 
the groups were observed and monitoring of DCs was precluded in Paper V due the low 
occurrence of DCs in blood. There are several factors that influence the thymic output 
following HSCT, including, age, GVHD, source of graft, and T cell depletion422. No 
significant differences in these factors were detected between the non-responders and the 
responders in Paper V.  
GVHD and other inflammatory conditions of the intestine are characterized by an influx of 
immune cells to the site of inflammation. The integrins α4β7 and the chemokine receptor 
CCR9 facilitate homing to the gut423. More specifically, an increased expression of α4β7 on T 
cells is associated with the development of GVHD in experimental models and in 
patients214,424. Therapy targeting α4β7 or CCR9 has been implemented in Crohn’s 
disease425,426 and ulcerative colitis427. The implementation of these strategies in GVHD has 
not yet been published, but it is an appealing concept. In Paper V, we investigated the 
expression of these molecules in most of the immune cell subsets evaluated. There was a 
difference between the responders and the non-responders in CD4+ T cells. At 4 weeks after 
the first DSC intervention, the responders had a higher frequency of CCR9 expression among 
the CD4+ T cells than the non-responders. Moreover, the responders had a higher frequency 
of B cells expressing CCR9. In the same group, among the monocytes that were CCR9+, the 
intensity of CCR9 expression was increased in both classical and non-classical monocytes at 
2 weeks compared to before or 3h after DSC intervention. However, the frequencies of 
monocytes that were CCR9+ did not differ significantly in any monocyte population 
investigated―between groups or over time. A small but significant increase in the frequency 
of α4β7+ in activated CD4+CD25+ T cells distinguished the responders between 3h and 4 
weeks following DSC treatment. The combined data suggest an increased homing ability of 
immune cells to the intestine following DSC treatment, and that this is associated with 
patients that have an improvement in their GVHD. The lack of findings in the subsets with a 
functional phenotype in the T and B cell compartment makes the determination of biological 
function in the CCR9+ and α4β7+ cells difficult.  
Altogether, in Paper V we identified three soluble molecules (IL-6, IL8, and IP-10) that 
distinguished patients who had an improvement in GVHD status from non-responsive 
patients following DSC treatment. In addition, patients who had an improvement in GVHD 
appeared to have an effector phenotype in the T cell compartment, and increased expression 
of gut-homing markers over time. 
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5 CONCLUSIONS AND FUTURE WORK 
5.1 CONCLUSIONS, PAPERS I‒V 
Stromal cells from the placenta can be isolated from various compartments. Depending of the 
compartment of the placenta, these cells have slightly different properties. In our pursuit of 
finding a cell subset suitable for cellular therapy for inflammatory conditions following 
HSCT, DSCs were found to: 
• Be easily isolated and expanded from the fetal membranes of term placentas. 
• Express surface markers associated with mesenchymal stromal cells. 
o Have elevated expression of CD49d, CD29, PD-L1,and ICAM-1. 
• Have limited differention capacity. 
• Be of maternal origin. 
Moreover, our studies in vitro in the allogeneic setting suggested that DSCs: 
• Have an immunosuppressive effect that may be partly contact-dependent. 
• Can directly inhibit proliferation of stimulated T cells. 
• Promote an anti-inflammatory cytokine profile. 
• Can be affected by exogenous IFN-γ and  
o Upregulate expression of integrins and inhibitory markers, while HLA class II 
expression is unchanged. 
o Do not necessarily retain increased suppressive capacity. 
• Are dependent on several molecules for their immunosuppressive function, including 
but not limited to: IDO, PD-L1, PGE2, and IFN-γ. 
• Promote Tregs in the allogeneic setting, partly dependent on IDO and cell contact. 
• Reduce IL-2R expression, STAT5 phosphorylation and IL-2 internalization.  
• May affect the antiproliferative effect of immunosuppressive drugs such as SRL. 
In addition, patients treated with DSCs for GVHD: 
• Can―based on GVHD response―be distinguished before treatment based on 
cytokine levels of IL-6, IL-8, and IP-10. 
• Have increased expression of gut-homing markers and a reduced frequency of naïve 
CD4+ T cells correlated to clinical response. 
• Showed a 75% overall response rate. Three out of eight evaluable patients were alive 
six months after transplantation.  
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5.2 FUTURE WORK 
The work in this thesis shows some examples of how the DSCs that we isolate and expand 
may influence immune parameters, both in vitro and in vivo.  
The focus was to investigate DSCs in the context of suitability for immunotherapy in 
comparison to existing sources of cells. Studies on DSCs and interaction with immune cells, 
such as macrophages, may further elucidate their function in tissues. Moreover, the putative 
role of DSCs in pregnancy success and their importance in feto-maternal tolerance need to be 
better established. Further investigations of immune cells at the feto-maternal interface could 
help identifying immune cell phenotypes that can be investigated in more detail.  
A continuation based on Papers III and IV is to investigate in greater detail why DSCs 
promote IL-2 production. Also, the role of PGE2 in this setting has not been determined. Are 
these results relevant in vivo, and do DSCs interact with immunosuppressants in a manner 
that is of clinical significance? The experiments in Paper IV begin to explore this interaction 
but further studies may unveil the full clinical impact.  
In Paper II, DSCs were introduced as a treatment for severe GVHD. In order to determine 
the efficacy of these cells, there is a need for a larger (preferably randomized) trial to 
determine their clinical importance for reduction of GVHD. Apart from evaluation of the 
clinical effect following DCS intervention, the data in Paper V would benefit from a control 
group in determining markers for successful DSC immunotherapy. GVHD is a complex 
disease, and the potential influence of DSCs in restoring homeostasis might involve aspects 
other than immunoregulation. For instance, recent work regarding GVHD has highlighted the 
importance of regeneration of intestinal epithelium for the restoration of gut homeostasis. 
DSCs production of certain cytokines (e.g. IL-22) and other factors of importance have not 
been investigated.  
The fate of DSCs and other stromal cells after administration in man has not been monitored 
in great detail, and to determine this in the clinical setting may be key in defining what 
contributes to a clinical effect. As mentioned, if DSCs are injured by complement upon 
administration, the cells would only exert a brief hit-and-run effect. In this sense, cellular 
therapy may be exchanged for exosomes or other membrane vesicles, which would be able to 
transport a wide variety of effector molecules derived from the cells of interest without the 
introduction of the entire cell to the patient.     
In this thesis, the focus has been on GVHD treatment. However, there are many other 
inflammatory disorders where DSC therapy could be considered, such as acute respiratory 
distress syndrome, autoimmune neuropathies and inflammatory bowel disease.  
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